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Sarcomas are uncommon but diverse mesenchymal malignancies arising from connective tissues, such
as muscle, fat and cartilage. Despite rapid advances in molecular understanding of individual subtypes
and pathway-specific therapies, the remarkable cellular and genetic heterogeneity of soft tissue sarcomas
(STS) limits clinical benefit of targeted treatments. A variety of metabolism-associated oncogenic
signaling pathways have been identified in sarcomas. Both these internal and external alterations
converge to change cell metabolism, rendering sarcoma cells more susceptible to perturbations within
metabolic networks. However, how abnormal metabolism influences sarcoma growth remains
understudied.
I show that expression of the gluconeogenic isozyme fructose-1,6-bisphosphatase 2 (FBP2) is silenced in
a broad spectrum of STS subtypes, revealing an apparent common metabolic feature shared by diverse
STS. Enforced FBP2 re-expression inhibits STS cell and tumor growth through two distinct mechanisms.
First, cytosolic FBP2 antagonizes elevated glycolysis associated with the “Warburg effect”, thereby
inhibiting sarcoma cell proliferation. Second, nuclear-localized FBP2 restrains mitochondrial biogenesis
and respiration in a catalytic activity-independent manner by inhibiting the expression of nuclear
respiratory factor (NRF1) and mitochondrial transcription factor A (TFAM). Specifically, nuclear FBP2
colocalizes with the c-Myc transcription factor at the TFAM locus and represses c-Myc-dependent TFAM
expression. This unique dual function of FBP2 provides a rationale for its selective suppression in STS,
identifying a potential metabolic vulnerability and possible future therapeutic target.
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ABSTRACT
FRUCTOSE-1,6-BISPHOSPHATASE 2 INHIBITS SARCOMA PROGRESSION BY
RESTRAINING MITOCHONDRIAL BIOGENESIS
Yangpeiwei Huang
M. Celeste Simon

Sarcomas are uncommon but diverse mesenchymal malignancies arising from connective
tissues, such as muscle, fat and cartilage. Despite rapid advances in molecular understanding of
individual subtypes and pathway-specific therapies, the remarkable cellular and genetic
heterogeneity of soft tissue sarcomas (STS) limits clinical benefit of targeted treatments. A variety
of metabolism-associated oncogenic signaling pathways have been identified in sarcomas. Both
these internal and external alterations converge to change cell metabolism, rendering sarcoma
cells more susceptible to perturbations within metabolic networks. However, how abnormal
metabolism influences sarcoma growth remains understudied.

I show that expression of the gluconeogenic isozyme fructose-1,6-bisphosphatase 2 (FBP2) is
silenced in a broad spectrum of STS subtypes, revealing an apparent common metabolic feature
shared by diverse STS. Enforced FBP2 re-expression inhibits STS cell and tumor growth through
two distinct mechanisms. First, cytosolic FBP2 antagonizes elevated glycolysis associated with the
“Warburg effect”, thereby inhibiting sarcoma cell proliferation. Second, nuclear-localized FBP2
restrains mitochondrial biogenesis and respiration in a catalytic activity-independent manner by
inhibiting the expression of nuclear respiratory factor (NRF1) and mitochondrial transcription factor
A (TFAM). Specifically, nuclear FBP2 colocalizes with the c-Myc transcription factor at the TFAM
locus and represses c-Myc-dependent TFAM expression. This unique dual function of FBP2
provides a rationale for its selective suppression in STS, identifying a potential metabolic
vulnerability and possible future therapeutic target.
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CHAPTER 1 INTRODUCTION
This chapter has been adapted from the following review article: Huangyang, Peiwei, and M.
Celeste Simon. "Hidden features: exploring the non-canonical functions of metabolic enzymes."
Disease models & mechanisms 11.8 (2018): dmm033365.
https://dmm.biologists.org/content/11/8/dmm033365.abstract

Introduction to soft tissue sarcomas
Soft tissue sarcomas (STS) encompass a diverse group of mesenchymal tumors arising from
connective tissues, such as muscle, fat and cartilage. Each year, approximately 13,000 new cases
are diagnosed in the United States, and 5,000 patients succumb to this disease (Siegel et al., 2019).
Collectively, STS are classified into more than 70 subtypes based on pathological and clinical
features, ranging from indolent to highly invasive and metastatic (Cancer Genome Atlas Research
Network, 2017; Fletcher, 2014). Liposarcoma, undifferentiated pleomorphic sarcoma (UPS), and
fibrosarcoma represent 40% of newly diagnosed sarcomas in adults (Lehnhardt et al., 2009).
Although recent studies have integrated genome-scale analyses of the molecular mechanisms
underlying sarcomagenesis and progression (Cancer Genome Atlas Research Network, 2017;
Taylor et al., 2011), these cancers remain understudied due to their extensive heterogeneity.
Current treatment options are limited to standard surgical resection, radiotherapy and
chemotherapy (Mehren et al., 2018); however, response rates to cytotoxic chemotherapy are only
10-25% (Linch et al., 2014). Highly divergent genomic alterations and low response rates to
traditional treatments necessitate development of effective therapies that exploit common features
of sarcoma progression.

Metabolic alterations in soft tissue sarcomas
Various oncogenic signaling pathways and microenvironmental stresses converge to modify
cellular metabolism, adapting it to limited nutrient and oxygen availability (Vander Heiden and
DeBerardinis, 2017). A broad array of oncogenes and tumor suppressors that regulate metabolic
pathways are mutated in sarcomas, such as PIK3CA (catalytic subunit of phosphatidylinositol 3-
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kinase), TP53, and NF1 (Barretina et al., 2010; Cancer Genome Atlas Research Network, 2017).
In

addition

to

effects

imposed

by

genetic

mutations,

hypoxic

(O2-deprived)

tumor

microenvironments characteristic of STS alter metabolism and are associated with worse prognosis
(Brizel et al., 1996; Sadri and Zhang, 2013). While reprogrammed metabolic activities likely
promote sarcoma growth and progression, they also create unique vulnerabilities and therefore
new opportunities for therapeutic intervention. Previously, labeled isotope infusion of sarcoma
patients revealed elevated tissue glucose uptake and turnover, accompanied by decreased
glucose oxidation (Shaw et al., 1988), suggesting abnormal glucose metabolism in these tumors.
Glycolysis is counterbalanced by anabolic gluconeogenesis to maintain glucose homeostasis, and
gluconeogenic enzymes play important roles in regulating tumor cell growth and behavior (Wang
and Dong, 2019).

Introduction to fructose-1,6-bisphosphatase and its role in cancer
Fructose-1,6-bisphosphatase (FBP) is a rate-limiting enzyme that catalyzes the irreversible
hydrolysis of fructose-1,6-bisphosphate to fructose-6-phosphate and inorganic phosphate.
Vertebrates possess two highly conserved FBP isozymes exhibiting 76.6% sequence identity:
FBP1 is detected primarily in liver and kidney, whereas FBP2 expression is more ubiquitous
although highest in skeletal muscle and other mesenchymal tissues. Recently, FBP1 loss has been
found to contribute to the progression of multiple epithelial tumors, including clear cell renal cell
carcinoma

(ccRCC),

breast

cancer,

hepatocellular

carcinoma

and

pancreatic

ductal

adenocarcinoma (Dong et al., 2013; Hirata et al., 2016; Li et al., 2014; Zhu et al., 2015). Several
mechanisms are implicated in downregulating FBP1, including transcription factor repression (Zhu
et al., 2015), epigenetic silencing (Bigl et al., 2008; Chen et al., 2011; Yang et al., 2017) and
proteasome degradation (Jin et al., 2017).

Restoration of FBP1 expression in breast cancer and ccRCC cells strongly antagonizes
glycolysis through its catalytic activity (Dong et al., 2013; Li et al., 2014); however, FBP1 also
regulates genes in ccRCC cells through an unanticipated nuclear function. Specifically, we
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demonstrated that FBP1 directly suppresses the transcriptional activity of hypoxia-inducible factors
(HIFs) through an enzymatic activity-independent mechanism (Li et al., 2014). HIFs regulate
several hundred genes, including those encoding the glycolytic enzymes GLUT1, HK2, PFK1 and
LDHA, to facilitate cellular adaptation to hypoxia (Nakazawa et al., 2016b); thus, FBP1 loss further
enhances HIF responses. Interestingly, over 90% of ccRCC tumors harbor von Hippel-Lindau (VHL)
mutations that stabilize HIFs even under normoxia (Nickerson et al., 2008). However, in pVHLexpressing ccRCC cells, FBP1 no longer inhibits glycolysis and NADPH production, suggesting
that HIFs are required for FBP1-mediated effects on glucose metabolism. Further investigation
found that FBP1 physically interacts with both HIF-1a and HIF-2a, and suppresses HIF target gene
expression by co-localizing with HIF-1a at hypoxia-responsive elements (HREs) within these loci.
Additionally, the suppression of HIF activity is abolished when a nucleus-excluded FBP1, but not
the catalytically dead FBP1, is introduced into ccRCC cells (Li et al., 2014). These data suggest
that FBP1’s activity as a HIF transcriptional co-repressor is restricted to the nucleus in a catalyticactivity independent manner.

Whereas FBP1 has been studied in a variety of carcinomas, little is known about the role of
FBP2 in mesenchymal cells or STS. The consensus nuclear localization sequence between FBP1
and FBP2 indicates that FBP2 might also preserve some previously unknown nuclear functions,
which might also be involved in inhibiting sarcoma progression.

Non-canonical functions of metabolic enzymes
With the development of new experimental techniques, advances in cancer metabolism research
have greatly enhanced our understanding of how cancer cells benefit from altered metabolism to
support their growth. For example, subcellular fractionation revealed that a majority of key glycolytic
enzymes are actually present in the nucleus (Kim and Dang, 2005). It is intriguing to speculate that
these enzymes have unexpected nuclear functions, such as stimulating gene expression, which
impacts specific cell decisions in response to fuel supply and demand. An emerging paradigm
proposes that metabolic enzymes, rather than simple components of biochemical pathways, are
multi-functional proteins. They can act as mediators between growth stimuli, signaling pathways
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and downstream effectors, over and above the changes in metabolism contributing to many other
biological functions, such as gene transcription, apoptosis, and cell-cycle progression.

A key finding from studies of metabolic enzymes is the existence of mechanistic links between
their nuclear localization and the regulation of transcription. By modulating gene expression,
metabolic enzymes themselves facilitate adaptation to rapidly changing environments. Furthermore,
they can directly shape a cell’s epigenetic landscape (Kaelin and McKnight, 2013). Strikingly,
several metabolic enzymes exert completely distinct functions in different cellular compartments.
Nuclear fructose bisphosphate aldolase, for example, directly interacts with RNA polymerase III to
control transcription (Cieśla et al., 2014); whereas in the cytosol, it mediates signal transduction,
vesicle trafficking and cell motility (Lincet and Icard, 2015). Indeed, a growing list of multifaceted
enzymes supports the possibility that cells employ existing proteins in different and efficient ways,
without the need to replicate or transcribe additional genes. We provide an overview of metabolic
enzymes for which non-canonical functions have been identified (Table 1) and their implications in
cancer.

Summary
The central goal of this study was to characterize the metabolic and transcriptional impacts of
FBP2 on sarcoma progression. We demonstrate here that FBP2 transcription is markedly silenced
in the majority of STS subtypes, and that restoring FBP2 expression dramatically inhibits sarcoma
cell proliferation in vitro and tumor growth in vivo, implicating FBP2 loss as an important general
event during sarcomagenesis. Isotope tracing and unbiased mass spectrometry analyses of
liposarcoma, fibrosarcoma and UPS cells demonstrated that glycolysis and TCA cycle activity are
inhibited by FBP2 restoration. Additionally, RNA-seq analysis indicates that mitochondrial function
and oxidative phosphorylation (OXPHOS) gene signatures are significantly repressed by FBP2.
Both FBP1 and FBP2 isozymes share a consensus nuclear localization sequence (NLS) (Gizak et
al., 2009a; 2009b), and a nucleus-excluded FBP2 mutant has no effect on mitochondrial biogenesis
and OXPHOS, indicating that nuclear FBP2 regulates mitochondrial function independent of its
enzymatic activity. Finally, we determined that FBP2 co-localizes with c-Myc at the promoter region
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of TFAM, which encodes a master regulator of mitochondrial biogenesis, and inhibits c-Mycmediated TFAM expression.
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Table 1. Summary of metabolic enzymes with non-canonical functions.
Enzymes
Hexokinase 2
(HK2)

Canonical
functions
Phosphorylate
glucose to glucose
6-phosphate
(G6P)

Phosphogluco
se isomerase
(PGI)

Interconvert G6P
to fructose 6phosphate (F6P)

Phosphofructo
kinase (PFK)

Phosphorylate
F6P to fructose 1,
6-bisphosphate
(F1, 6BP)

6phosphofructo
se-2kinase/fructose
-2, 6bisphosphatas
e 3 (PFKFB3)
Fructose-1, 6bisphosphatas
e 1 (FBP1)

Interconvert F6P
to fructose 2, 6bisphosphate (F2,
6BP)

Aldolase A

Split F1, 6BP to
dihydroxyacetone
phosphate (DHAP)
and
glyceraldehyde 3phosphate (G3P)
Interconvert G3P
to 1, 3bisphophoglycerat
e (1, 3BPG)

Glyceraldehyd
e 3-phosphate
dehydrogenas
e (GAPDH)

Hydrolyze F1, 6BP
to F6P

Non-canonical functions

Refs

Represses the expression of
genes involved in glucose
repression
Mitochondrial HK2 protect cells
from apoptosis by regulating the
mitochondrial permeability
transition pore and by limiting the
production of reactive oxygen
species
Acts as an autocrine factor
extracellularly to elicit cell
migration and proliferation

(Ahuatzi et al., 2004;
Cheung et al., 2012; Chiara
et al., 2008; Gottlob et al.,
2001; La Cera et al., 2002;
Majewski et al., 2004; Neary
and Pastorino, 2013;
Pastorino et al., 2002)

Nuclear PFK1 binds to
transcription factor TEAD and
stabilizes its interaction with
YAP/TAZ and promotes gene
expression
Nuclear PFKFB3 promotes cellcycle progression by upregulating
cell-cycle protein expression and
downregulating cell-cycle inhibitor
p27

(Ahmad et al., 2011; Fu et
al., 2011; Funasaka et al.,
2007a; 2007b; Sun et al.,
1999; Watanabe et al.,
1996)
(Enzo et al., 2015)

(Yalcin et al., 2014; 2009)

Nuclear FBP1 binds to HIFs and
inhibits its transcriptional
activation of glycolytic gene
expression
Nuclear aldolase A is involved in
the cytokinesis through its
interaction with F-actin and
Wiskott-Aldrich Syndrome Protein
(WASP) family proteins

(Li et al., 2014)

Binds to colony-stimulating factor1 (CSF-1) mRNA and stabilizes
its transcripts
GAPDH is a key component in
OCA-S complex, mediates its
activation of H2B during S phase
and promotes cell-cycle
progression
Protects telomeres against rapid
shortening
Increases DNA synthesis during
S phase via direct binding to
ssDNA and stimulating the DNApolymerase-a-primase complex
GAPDH S-nitrosylation promotes
its nuclear translocation and
triggers apoptosis
Mitochondrial GAPDH facilitates
apoptosis via inducing
mitochondrial membrane
permeabilization (MOMP) and

(Grosse et al., 1986; Hara et
al., 2005; Ishitani et al.,
1996; Ishitani and Chuang,
1996; Sen et al., 2009;
2008; Sundararaj et al.,
2004; Zheng et al., 2003;
Zhou et al., 2008)
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(Buscaglia et al., 2006; Kao
et al., 1999; Ritterson Lew
and Tolan, 2012)

Phosphoglycer
ate kinase
(PGK)
Enolase 1
(ENO1)

Interconvert 1,
3BPG to 3phosphoglycerate
(3PG)
Interconvert 2phosphoglycerate
to
phosphoenolpyruv
ate (PEP)

Pyruvate
kinase 2
(PKM2)

Transfer a
phosphate group
from PEP to ADP
to yield pyruvate
and ATP

Lactate
dehydrogenas
e A (LDHA)

Interconvert
lactate to pyruvate

Aconitase

Interconvert citrate
to isocitrate in the
TCA cycle
Interconvert
sucinyl-CoA to
succinate in the
TCA cycle
Interconvert
fumarate to malate
in the TCA cycle
Interconvert
malate to

Succinyl-CoA
synthase
(SCS)
Fumarase
Malate
dehydrogenas
e (MDH)

subsequent release of
cytochrome c and AIF
Recognizes primer and robustly
stimulates DNA synthesis
catalyzed by DNA polymerase a
and e
MYC binding protein-1 (MBP-1)
transcribes from the same gene
as ENO1; MBP-1 binds to MYC
and represses its expression by
recruiting histone deacetylase
(HDAC)
MBP-1 attenuates Notch1mediated c-Myc activation by
interacting with activated Notch1
receptor, N1IC
Acts as a binding partner of Oct-4
and enhances its transcriptional
activity
Interacts with HIF1a and
increases p300 recruitment to HIF
target gene
Upon EGFR stimulation, PKM2
binds to b-catenin and coactivates cyclin D1 and c-Myc
Kinase activity (controversial):
PKM2 phosphorylates a variety of
proteins, such as stat3, Histone
H3, Bub3 and myosin light chain
2 (MLC2). PKM2 promotes G1/S
transition by promoting cyclin D1
and c-Myc expression and
chromosome segregation by
phosphorylating spindle
checkpoint protein Bub3
In yeast, Pyk1 (yeast PKM2)
forms the SESAME complex.
SESAME interacts with Set1
methyltransferase and controls
H3K4me3
Forms OCA-S complex with
GAPDH and regulates cell-cycle
progression
Activates SIRT1 by
supplementing NAD+
Binds to ssDNA and facilitates
DNA replication by recruiting with
DNA polymerase a, d, and e
In yeast, aconitase (Aco1p) is
essential for mtDNA maintenance

(Kumble and Vishwanatha,
1991; Popanda et al., 1998)
(Feo et al., 2000; Ghosh et
al., 1999a; 1999b; Hsu et al.,
2008; Wang et al., 2005)

(Gao et al., 2012; Hosios et
al., 2015; Jiang et al.,
2014a; 2014b; Lee et al.,
2008; Li et al., 2015; Luo et
al., 2011; Wang et al., 2014;
Yang et al., 2012a; 2011;
2012b)

(Castonguay et al., 2014;
Popanda et al., 1998; Zheng
et al., 2003)

(Chen et al., 2005)

SCS-A is associated with mtDNA
maintenance

(Phillips et al., 2009)

Participates in DNA damage
repair in an enzymatic activity
dependent manner
Increases p53 stabilization and
transcriptional activity by

(Jiang et al., 2015; Yogev et
al., 2010)

7

(Lee et al., 2009; McEwen et
al., 1963)

Pyruvate
dehydrogenas
e complex
(PDC)

oxaloacetate in the
TCA cycle
Convert pyruvate
to acetyl-CoA

ATP-citrate
lyase (ACLY)

Convert citrate to
oxaloacetate and
acetyl-CoA

Acetyl-CoA
synthetase
short-chain
family member
2 (ACSS2)

Catalyze acetate
to acetyl-CoA

Methionine
adenosyltransf
erase IIa
(MATIIa)

Produce Sadenosylmethionin
e (SAM) from
methionine

Serine
hydroxymethylt
ransferase
(SHMT)

Interconvert Lserine to glycine
and
tetrahydrofolate to
5, 10methylenetetrahyd
rofolate

facilitating its phosphorylation and
acetylation
Produces acetyl-CoA in the
nucleus and increases histone
acetylation
Promotes cell-cycle progression
by increasing acetylation of
histones important for G1/S
transition and activating S-phase
regulator expression (P-Rb, E2F,
cyclin A, and Cdk2)
Produces acetyl-CoA and
increases histone acetylation
Upon DNA damage, nuclear
ACLY promotes homologous
recombination
Forms a complex with TFEB and
increases lysosomal and
autophagy gene expression by
local histone acetylation
Provides acetyl-CoA for lysine
acetyltransferase CREB-binding
protein (CBP)-mediated HIF-2a
acetylation
Forms a complex with Maf and
represses HO-1 expression by
increasing histone methylation
and recruiting chromatin
corepressors
Directs deubiquitinating complex
BRISC to IFAR1 and protects it
from lysosomal degradation and
promotes IFNAR1 signaling
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(Cai et al., 2011; Kim et al.,
2006; Sutendra et al., 2014)

(Lee et al., 2014; Sivanand
et al., 2017; Wellen et al.,
2009)
(Cheng et al., 2015; Li et al.,
2017a; 2017b; Zhao et al.,
2016)

(Katoh et al., 2011)

(Zheng et al., 2013)

CHAPTER 2 MATERIALS AND METHODS
Cell culture
LPS224, LPS246, T449, T778, T1000, SW872, HT1080, KP250 and 293T cells were tested to
confirm they are mycoplasma negative, and cultured in DMEM (Life Technologies, 11965-084)
containing 10% FBS (Gemini, 900-108). C2C12 myoblasts (ATCC, CRL-1772) were propagated in
DMEM containing 20% FBS. To evaluate differentiation, myoblasts were grown to 80 to 90%
confluence and switched to 2% horse serum (Life Technologies, 16050-122) in DMEM. For
metabolic labelling assays, cells were maintained in glucose-free DMEM (Life Technologies,
11966-025) supplemented with 10% dialyzed FBS (Gemini, 100-108) and 10 mM [1, 2-13C]glucose
(Sigma-Aldrich, 453188), or supplemented with 10% dialyzed FBS and 2 mM [3-13C]sodium
pyruvate (Sigma-Aldrich, 490733). Human skeletal muscle myoblasts (HSMM, Lonza, CC-2580)
were culture in SkBM-2 Basal Medium (Lonza, CC-3246), supplemented with SkGM-2 SingleQuots
containing GA-1000, human Epidermal Growth Factor, Dexamethasone and L-glutamine (Lonza,
CC-3244). Differentiation should be initiated when the plated myoblasts reach 80-90% confluence
and differentiation medium (DMEM with 2% horse serum) was added to the plates and changed
every 2-3 days. All cells were incubated at 37°C and 5% CO2.

Mice
Xenograft tumor experiments were approved by the Animal Care and Use Committee at the
University of Pennsylvania. Briefly, ten female NSG mice (the Jackson Laboratory, 6 weeks,
005557) were injected subcutaneously into both flanks with 2 million LPS246 cells stably
expressing TetOne-FBP2. Before injection, cells were resuspended in 100 µl PBS mixed with an
equal volume of Matrigel (Corning, 356234). Once palpable tumors were established, tumor volume
was measure with a digital caliper. When the average tumor size reached 100 mm3, ten mice were
randomly separated into two groups: (1) Doxycycline diet (Bio-Serv, S3888) and (2) control diet
(Bio-Serv, S4207). Upon completion of the experiment, the animals were sacrificed by CO2
inhalation and xenograft tumors were dissected for downstream analyses.
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Constructs and Viral Transduction
Lentivirus was produced by transfecting 2.5 × 106 HEK293 cells with the 10 µg indicated
expression plasmid, 2.5 µg pRSV-Rev, 6.5 µg pMDL, and 3.5 µg pCMV-VSV-G plasmids (4th
generation lentiviral system) using FuGENE 6 Transfection Kit (Promega, E2691). The virus was
harvested 48 h after transfection by filtering the virus-containing medium through Amicon Ultra-15
Centrifugal Filter (Millipore, UFC901024). Virus infection was performed by incubating cells with
medium containing indicated virus and 8 µg/ml polybrene (Sigma, 107689) for 24 h. Cells were
allowed to recover in complete medium for 24 h and then selected with puromycin for 48 h.
Surviving pools were subjected to indicated experiments.

Sequence verified cDNA constructs were obtained from the Mammalian Gene Collection (GE
Dharmacon) and were subcloned into the pCDH-CMV-MCS-EF1-Puromycin mammalian
expression vector (System Biosciences CD510B-1) and pLVX-TetOne-Puro (Clontech, 631847).
FBP2 cDNA construct: MHS6278-211687897 (Accession, BC117477). The FBP24KA and
FBP2G260R mutants were generated using Q5 Site-Directed Mutagenesis Kit (NEB, E0554).
FBP24KA

Forward

primer:

5’-

caggagcgatttacagcctgaatgag-3’,

Reverse

primer:

5’-

ccgccgcaatcttgacatctttttccac-3’. FBP2G260R Forward primer: 5’-cctggtctatagaggaatcttcctgtaccc-3',
Reverse primer: 5'-gtgcggtgcacgtcagcc-3'.

RNA Interference
LPS246 cells were plated in 6-well plate at a density of 2.5 × 105 cells per well. siRNA pools
targeting human c-Myc (sc-29226) was obtained from Santa Cruz Biotechnology and non-targeting
pool control (D-001810-10-05) was obtained from Dharmacon. For each well, 100 µl OPTI-MEM
(Thermo Fisher Scientific, 31985062), 24 µl sic-Myc or non-targeting pool control (10 nM) and 12
µl HiPerfect transfection reagent (Qiagen, 301705) were mixed and incubated before loaded to the
plate.
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Cell Growth Assays
Multiple cultures of LPS246, T1000, SW872, and KP250 cells were plated in 60 mm plates at a
density of 8 × 104 cells supplemented with DMEM containing 1% FBS. Every other day, one set of
cultures was collected and counted. Multiple cultures of LPS246, T1000, SW872, and HT1080 cells
were plated in 60 mm plates at a density of 5 × 104 cells with either glucose-free DMEM
supplemented with 10% FBS and 5 mM D-(+)-Glucose (Sigma-Aldrich, G8270) or DMEM
containing 10% FBS. Every day, one set of cultures was collected and counted every day.

Anchorage-Independent Growth Assay
Sarcoma cells (SW872, HT1080, KP250) stably expressing FBP2 or vector control were plated
in 6-well plates at a density of 6,000 cells per well in complete medium containing 0.3% agarose
(low-melt 2-hydroxyethylagarose, Sigma-Aldrich, A4018), onto underlays composed of medium
containing 0.6% agarose. Additional media was added to the cultures once per week, and after two
weeks of growth the colonies were quantified.

Western Blot Analysis
Cells were harvested in lysis buffer (150 mM NaCl, 10 mM Tris pH 7.6, 0.1% SDS and 5 mM
EDTA) containing Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific,
78445). For western blots of xenograft tissue, approximately 20-30 mg of tissue was suspended in
500 µl lysis buffer and homogenized on ice using a Tissue-Tearor (Biospec, 985370). Samples
were centrifuged at 12,000 rpm for 20 min at 4 °C. Protein lysates were resolved by Tris-Glycine
SDS-PAGE and were transferred to nitrocellulose membranes (Bio-Rad, 162-0115, 0.45 µm pore
size for all experiments). All membranes were incubated with the indicated primary antibodies
overnight at 4 °C and were diluted in TBST (20 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween-20)
supplemented with 5% bovine serum albumin (BSA, Sigma-Aldrich, A7906). Primary antibodies
were detected with horseradish peroxidase-conjugated secondary antibodies followed by exposure
to ECL reagents.
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Co-Immunoprecipitation
LSP246 cells expressing FBP2 or FBP24KA were incubated in Co-IP lysis buffer (20 mM Tris HCl
pH 8, 137 mM NaCl, 1% NP-40 and 2 mM EDTA) supplemented with Halt Protease and
Phosphatase Inhibitor Cocktail for 20 min at 4 °C. Collect the lysates and centrifuge at 12,000 rpm
for 10 min at 4 °C. Transfer the supernatant to a clean tube and save 1/10 lysate as input. Preclean the rest lysate by adding 50 µl Protein Agarose A/G bead slurry (Thermo Fisher Scientific,
20421) and 2 µl mouse IgG (Cell Signaling Technology, #5415) and rotate at 4 °C for 2 hours. Spin
down the beads. The lysates were evenly separated and incubated with IgG or V5 antibody
(Thermo Fisher Scientific, #R960-25) at 4 °C overnight. 35 µl Protein Agarose A/G bead slurry was
incubated with lysates for additional 2 hours. Wash the beads with Co-IP lysis buffer three times
and add 2 × loading buffer (0.5 M Tris-HCl pH 6.8, 4.4% SDS, 20% glycerol, 2% 2-mercaptoethanol,
0.1% bromophenol blue) to elute the bound proteins.

GST pull-down
The cDNA fragment of c-Myc was obtained from Addgene (102626) and was amplified and
cloned into pGEX fusion with glutathione S-transferase (GST) as the bait using primers (F: CGC
GGATCCATGGATTACAAGGATGACGACGATAAG, R: CCGGAATTCTTACGCACAAGAGTTCC
GTAGCT). FBP2 cDNA construct: MHS6278-211687897 (Accession, BC117477) was cloned into
pET-28a (+) plasmid as the prey for fusion with His-tag using the indicated primers (F: CGCGGATC
CATGACGGACAGAAGCCCCTTC, R: CCGGAATTCTCAATGGTGATGGTGATGATGACCGG).
Both bait and prey recombinant proteins were used to transform E. coli strain BL-21 for protein
expression. Both bait and prey proteins were blocked using 4% BSA (final concentration 0.8%) at
4 °C for 30 min. Combine both proteins with 60 µl Glutathione Sepharose 4B (17075601) and rotate
at 4 °C for 2 hours. Wash beads twice with PBS + 0.5% NP-40, once with PBS + 0.5% NP-40 +
300 mM KCl and twice with PBS + 0.5% NP-40. Resuspend the beads with 30 µl 2 × loading buffer
and boil the samples at 95 °C for 10 min.
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Quantitative RT-PCR
Total RNA was isolated from cells using the RNAeasy purification kit (Qiagen, 74104). cDNA
was synthesized using a High Capacity RNA-to-cDNA kit (Applied Biosystems, 4368814). qRTPCR was performed on a ViiA7 Real-Time PCR system from Applied Biosystems. Pre-designed
Taqman primers were obtained from Life Technologies for the following genes: 18S
(HS03928985_G1),

MT-ND1

(HS02596873_S1),

MT-MYB

(HS02596867_S1),

MT-CO1

(HS02596864_G1), and MT-ATP6 (HS02596862_G1), c-Myc (Hs00153408_m1), CCND2
(Hs00153380_m1),

eIF2A

(Hs00230684_m1),

NPM1

(Hs02339479_g1),

PSAT1

(Hs00795278_mH).

Chromatin Immunoprecipitation (ChIP) and ChIP-reChIP Assay
ChIP and ChIP-reChIP were performed as described previously (Si et al., 2015). Briefly, cells
were cross-linked using 1% formaldehyde at room temperature for 10 min. The cross-linking
reaction was quenched by glycine. Cells were lysed in SDS buffer containing protease inhibitor
cocktail and lysates were sonicated at 4 °C (30s on and 30s off, 15 cycles). The sheared chromatin
was precleared, and then subjected to immunoprecipitation with 5 µg IgG (Cell Signaling
Technology, 5415) and V5 (Thermo Fisher Scientific, R960-25) antibodies. After washing with lowand high-salt buffers, immunoprecipitated DNA fragments were eluted and purified with the
QIAquick PCR Purification Kit and then analyzed by qRT-PCR. For ChIP-reChIP, the first ChIP was
performed using c-Myc antibody (Santa Cruz Biotechnology, sc-40x), until the washing steps. The
immunoprecipitated protein-DNA complexes were incubated in ChIP-reChIP elution buffer (10 mM
Tris-HCl, pH 8.0, 2 mM EDTA, 2% SDS, 15 mM DTT, supplemented with protease inhibitor cocktail)
for 30 min at 37 °C. The isolated supernatant was diluted at least 20 times and subjected to the
second ChIP using 5 µg IgG or V5 antibodies.

mtDNA Content
Total DNA was extracted from cell samples using Wizard Genomic DNA Purification Kit
(Promega, A1120) according to the manufacturer’s instructions. To quantify mtDNA copy number,
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real-time PCR was performed using a on a ViiA7 Real-Time PCR system from Applied Biosystems
against MT-ND1 (HS02596873_S1) as the standard for mtDNA. The b-globin (HBB) was used as
the nuclear gene (nDNA) normalizer for calculation of the mtDNA/nDNA ratio, as previously
described (Dickinson et al., 2013). A fragment of HBB gene was amplified using forward primer,
5’-caacttcatccacgttcacc-3’, and reverse primer, 5’-gaagagccaaggacaggtac-3’. The relative mtDNA
content was calculated using the formula: mtDNA content = 1/2DCt, where DCt = CtmtDNA − CtHBB.

Subcellular Fractionation
Cytosolic and nuclear fractionation of indicated cells were performed using NE-PER nuclear and
cytoplasmic extraction reagents (Thermo Fisher Scientific, 78833) by following the manufacturer’s
protocol. Briefly, cells were trypsinized, washed using PBS and pelleted. Depending on the volume
of cell pellet, the ratio of CER I, CER II and NER were maintained at 200:11:100 µl (for 20 µl cell
pellet). Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, 78445) was
added to CER I and NER. Cells were first incubated with CER I for 10 min, followed by CER II for
1 min and centrifuged at 12,000 rpm for 5 min at 4 °C. The supernatant was saved as cytoplasmic
extract and the insoluble fraction was suspended in NER. Vortex for 15s every 10 min, for a total
of 40 min. Centrifuge at 12,000 rpm for 10 min at 4 °C and the supernatant is the nuclear extract.

FBP2 Enzymatic Activity Assay
Vector control 293T cells, or 293T cells expressing FBP2, FBP24KA or FBP2G260R were harvested
in lysis buffer used for western blot analysis. 20 µg lysates were added to 100 µl reaction buffer
containing 50 mM Tris (pH 6.8), 10 mM MgCl2, and 100 µM D-fructose 1,6- bisphosphate trisodium
salt (Sigma-Aldrich, F6803). The reaction was started by incubating solutions at 37 °C for 15 min
and stopped by a deproteinization protocol using Deproteinizing Sample Preparation Kit (BioVision,
K808). FBP2 catalytic activity was quantified according to the yield of fructose 6-phosphate
(enzyme product), measured by Fructose-6-Phosphate Fluorometric Assay Kit (BioVision, K689100).
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Cell Apoptosis Assay
LPS246 TetO-FBP2 (PBS or Dox treated) and LPS246 TetO-FBP24KA (PBS or Dox treated) cells
were seeded in 6-well plates at a density of 1.5 × 105 per well. These cells were incubated in 5 mM
glucose medium (glucose-free DMEM, 10% FBS, 5 mM glucose) or 5 mM galactose medium
(glucose-free DMEM, 10% FBS, 5 mM galactose). After 24 h, cells and supernatant were collected
and centrifuged. The cell pellet was suspended with 110 µl binding buffer. Cells were then stained
with the FITC-Annexin V Apoptosis Detection Kit (BD Biosciences, 556547) with Annexin V Alexa
Fluor 488 and propidium iodide (PI) and incubated for 15 min at room temperature in the dark. After
incubation, 400 µl of binding buffer was added and cells were analyzed by flow cytometry using the
BD Accuri C6 instrument. Double-negative cells were determined viable.

MitoTracker and MitoSox Staining
LPS246 TetO-FBP2 (PBS or Dox treated) and LPS246 TetO-FBP24KA (PBS or Dox treated) cells
were seeded in 6-well plates at a density of 1.5 × 105 per well. Cells were incubated with 5 µM
MitoSox reagent (Thermo Fisher Scientific, M36008) or 25-100 nM MitoTracker Green FM probe
(Thermo Fisher Scientific, M7514) at 37 °C for 30 min. Save one well of cell without staining as the
negative control. After staining was complete, the cells were gently washed three times with warm
PBS. Detach cells from plates and ensure a single cell suspension. Analyze the samples by flow
cytometry using BD Accuri C6.

ATP Measurements
ATP production was measured using the ATP Determination Kit (Thermo Fisher Scientific,
A22066) according to the manufacturer’s protocol. Briefly, cells were homogenized in lysis buffer
(1% Triton X-100, 0.1% SDS, 150 mM NaCl, 50 mM Tris-HCl pH 7.5) supplemented with protease
and phosphatase inhibitor cocktail (Thermo Fisher Scientific, 78445). Data were determined by
luminescence (Promega, Glomax 20/20 luminometer). Data were collected from multiple replicate
wells for each experiment and were normalized to protein concentration.
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Citrate Synthase Activity
Citrate synthase activity was measured on total cell extracts by Citrate Synthase Activity Assay
Kit (Abcam, ab119692). In brief, 100 µl of cell lysates was added to the pre-coated microplate strips,
sealed, and incubated at room temperature for 3 hours. The wells were aspirated and washed twice
with 300 µl wash buffer. Activity solution was added to the well and the plate was immediately read
every 20 seconds for 30 min at a wavelength of 412 nm using a plate reader (BioTek, Synergy H1).

Immunohistochemistry
LPS246 tumor sections and tissue microarray slides (US Biomax, SO801b) were deparaffinized
by baking slides at 60 °C for 30 min. The slides were rehydrated in series of ethanol solutions and
endogenous peroxidase activities were quenched by 1% H2O2 in distilled water for 20 min. After
three washes in TT buffer (500 mM NaCl, 10 mM Trizma, and 0.05% Tween-20), antigen retrieval
was performed by boiling slides for 20 min in a citrate-based antigen unmasking solution (Vector
labs, H3300). After cooling down to room temperature, slides were blocked in 2% normal goat
serum and 4% BSA in TT buffer for 1 h. Next, tissue slides were incubated with various primary
antibodies at 4 °C overnight. After three washes in TT buffer, biotinylated secondary antibody was
added onto these slides for 1 h, following by 1 h treatment of the Vectastain Elite ABC reagents
(Vector Labs, PK-6100). After three TT washes, the slides were processed with DAB peroxidase
substrate kit (Vector Labs, SK-4100), and hematoxylin solutions for immunohistochemistry staining,
dehydrated in a standard ethanol/xylene series, and mounted in 75% v/v Permount (Fischer
Scientific, SP15-500) in xylenes.

Tissue Immunofluorescence
LPS246 tumors were fixed in 4% paraformaldehyde (PFA)/PBS overnight at 4 °C. Fixed tissues
were dehydrated in 30% sucrose solution and embedded in OCT for frozen sectioning. Tissue
samples were submitted to the Molecular Pathology & Imaging Core (MPIC) at the University of
Pennsylvania for processing and sectioning. Frozen sections were rinsed in cold PBS to remove
OCT, and then incubated with 0.25% Triton-X-100 in PBS for 10 min at room temperature. The
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slides were incubated in a blocking buffer (4% BSA, 2% serum in PBS) for 1 h at room temperature.
The slides were then incubated with diluted primary antibodies in blocking buffer overnight at 4 °C.
After washing in PBS, the slides were further incubated with fluorescein-conjugated secondary
antibodies diluted in blocking buffer for 1 hour at room temperature. The slides were finally mounted
with ProLong Diamond Antifade Mountant with DAPI (Thermo Fisher Scientific, P36962). Slides
were examined and images were captured on a Leica DM5000B microscope.

Cell Immunofluorescence
Cells were plated in 2-well Chamber Slides (Lab-Tek, 154461). After 24 h, the cells were washed
three times with PBS and fixed for 20 min in 4% paraformaldehyde at room temperature. Cells were
permeabilized in PBS containing 0.5% Triton X-100 and blocked in PBS containing 5% BSA
(blocking buffer). Primary antibodies against FBP2 (Abcam, ab131253) and secondary antibodies
(Thermo Fisher Scientific, Alexa Fluor 488) were diluted in blocking buffer. Slides were washed
three times in PBS, rinsed in H2O, and mounted on slides using VectaShield mounting medium
containing 4’6’-diamidino-2-phenylindole (DAPI) (Vector Labs, H-1200).

Metabolic Quantification
The rate of glucose uptake and lactate secretion was determined using Multiparameter
Bioanalytical System (YSI Life Sciences, YSI 2950). Briefly, cells were seeded in 6 cm plates
starting with 4 replicates. The next day, the medium was changed to 10 mM glucose medium
(glucose-free and glutamine-free DMEM, 10% dialyzed FBS, 10 mM glucose, 2 mM glutamine).
Cells in one replicate ware trypsinized and counted. The cell number was labeled as Q1 (starting
cell number). 24 h later, culture medium was collected and read by YSI analyzer. Cell number was
counted as Q2 (final cell cell number). Measurements were normalized to cell number area under
the curve, as previously described (Gentile et al., 2013). Metabolite consumption was defined
as v = V(xmedium

control

− xfinal)/A, where v is metabolite consumption/production, V is culture

volume, x is metabolite concentration, and A is cell number area under the curve. A was calculated
as N(T)d/ln2(1 − 2−T/d), where N(T) is the final cell count, d is doubling time, and T is time of
experiment. Doubling time was calculated as d = (T)[log(2)/log(Q2/Q1)].
17
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C-metabolic Flux Analysis
Cells were seeded to 10 cm plates at a density of 1 million cells per plate. For [1,2-13C]glucose

labeling, cells were incubated in 10 mM [1,2-13C]glucose medium (glucose-free DMEM, 10% FBS,
10 mM [1,2-13C]glucose) for 24 h. For [3-13C]pyruvate labeling, cells were incubated in 2 mM [313

C]pyruvate medium (glucose-free DMEM, 10% FBS, 2 mM [3-13C]pyruvate) for 6 h. To measure

the

13

C enrichment in TCA cycle intermediates, [1,2-13C]glucose-labelled or [3-13C]pyruvate-

labelled cells were extracted by 4% perchloric acid (PCA). Briefly, cells were washed twice with
ice-cold PBS and then scraped in 4% PCA on dry ice, which was then freeze-thawed for three
cycles. Cell extracts were neutralized using 5 M KOH and analyzed as previously described (Nissim
et al., 2012). The neutralized PCA extract were subjected to an AG-1 column (100-200 mesh, 0.5
× 2.5 cm, Bio-rad) for enriching the organic acids, glutamate and aspartate, which were then
converted to t-butyldimethylsilyl derivatives. The production of

13

C-labeled metabolites was

measured using GC-MS. Isotopic enrichment in [13C]glutamate isotopomers was monitored using
ions at m/z 432, 433, 434, 435, 436 and 437 for M0, M1, M2, M3, M4 and M5 (containing 1 to 5 13C
atoms above M0, the natural abundance), respectively. Isotopic enrichment in [13C]aspartate
isotopomers was monitored using ions at m/z 418, 419, 420, 421 and 422 for M0, M1, M2, M3 and
M4 (containing 1 to 4

13

C atoms above M0, the natural abundance), respectively. Isotopic

enrichment in [13C]lactate was determined using ions at m/z 261, 262, 263 and 264 for M0, M1, M2
and M3 (containing 1 to 3 13C atoms above natural abundance), respectively. Isotopic enrichment
in [13C]pyruvate isotopomers was monitored using ions at m/z 259, 260, 261 and 262 for M0, M1,
M2 and M3 (containing 1 to 3 13C atoms above M0, the natural abundance), respectively. Isotopic
enrichment in [13C]malate isotopomers was monitored using ions at m/z 419, 420, 421, 422 and
423 for M0, M1, M2, M3 and M4 (containing 1 to 4
respectively, and

13

C atoms above M0, the natural abundance),

13

C enrichment in [13C]citrate isotopomers was assayed using ions at m/z 459,

460, 461, 462, 463, 464 and 465 for M0, M1, M2, M3, M4, M5 and M6 (containing 1 to 6 13C atoms
above M0, the natural abundance), respectively.
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Quantification of the Pentose Phosphate Pathway (PPP)
Metabolic flux going through the PPP was quantified as previously described (Lee et al., 1998),
using [1,2-13C]glucose as the labelling tracer. Briefly, direct glycolysis of [1,2-13C]glucose (without
going through the PPP) produces M2-labelled lactate, while flux going through the oxidative portion
of PPP removes the first carbon from glucose and releases it in the form of CO2. The resultant M1labelled intermediates are recycled back to glycolysis to produce M1-labelled lactate through the
non-oxidative potion of PPP. The ratio of M1 to M2-labelled lactate indicates the ratio of flux going
through the PPP versus flux directly going through glycolysis. Therefore, PPP flux was calculated
based on the following formula: PPP flux = glucose consumption × M1 lactate enrichment / (M1
lactate enrichment + M2 lactate enrichment). Calculated PPP flux was then normalized to vector
control cells by setting the vector control flux equal to 1.

Seahorse XF Cell Mito Stress Analysis
The mitochondrial respiratory capacity was determined using XF Cell Mito Stress Test Kit
(Agilent Technologies, 103015-100). Cells were seeded in the XF96 Cell Culture Microplate at a
density of 2 × 104 cells per well. 6 replicates were set up for each of the following groups: (1)
LPS246 TetO-FBP2 + Veh; (2) LPS246 TetO-FBP2 + Dox; (3) LPS246 TetO-FBP24KA + Veh; (4)
LPS246 TetO-FBP24KA + Dox. Microplate was incubated for 24 h at 37 °C. Seahorse XF96 FluxPak
sensor cartridge was hydrated in the utility plate filled with 200 µl of Seahorse Calibrant overnight
in a non-CO2 incubator at 37 °C. Next day, cells were incubated with the base medium containing
2 mM L-glutamine, 1 mM sodium pyruvate, and 10 mM glucose for 1 hour prior to assay. The
oxygen consumption rate (OCR) was measured by XFe96 extracellular flux analyzer with
sequential injection of 1 µM oligomycin A, 1 µM FCCP, and 0.5 µM rotenone/antimycin A. After the
experiment, cells lysates were harvested with 20 µl western blot lysis buffer and protein
concentration was quantified using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, 23225).
OCR value was normalized to the protein concentration in each well.
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Quantification and Statistical Analysis
All statistical analyses were conducted using GraphPad Prism 7.0. All error bars are presented as
mean ± s.d. unless otherwise specified. Data were reported as biological replicates. P values were
calculated based on two-tailed, unpaired Student’s t-tests. Significance was defined as *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001.
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Table 2. Key resources table.
REAGENT or RESOURCE
Antibodies
Rabbit monoclonal anti-FBP2
Rabbit polyclonal anti-FBP2 for IHC
Mouse polyclonal anti-FBP1
Rabbit polyclonal anti-PCK1
Rabbit polyclonal anti-G6PC
Rabbit monoclonal anti-GAPDH
Mouse monoclonal anti-HDAC1
Rabbit monoclonal anti-HSP90
Rabbit polyclonal anti-Phospho-Histone H3
Anti-rabbit IgG HRP-linked
Anti-mouse IgG HRP-linked
Mouse (G3A1) mAb IgG1 Isotype Control
Normal Rabbit IgG
NRF1 (D9K6P) Rabbit mAb
Rabbit monoclonal anit-VDAC1
Rabbit polyclonal anti-TOMM20
TFAM Polyclonal Antibody
Biotinylated Goat anti-Rabbit IgG
Mouse monoclonal anti-V5 Tag
Goat anti-Rabbit IgG (H+L) Secondary
Antibody, Alexa Fluor 488 conjugated
c-Myc Monoclonal Antibody (9E10)
Biological Samples
Soft tissue malignant tumor tissue array

SOURCE

IDENTIFIER

Abcam
Sigma-Aldrich
Sigma-Aldrich
Abcam
Abcam
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
ABclonal
ABclonal
ABclonal
Vector Labs
Thermo Fisher Scientific
Thermo Fisher Scientific

#ab131253
#HPA012513
#SAB1405798
#ab28455
#ab83690
#2118
#5356
#4877
#9701
#7074
#7076
#5415
#2729
#46743
#A11242
#A6774
#A13552
#BA-1000
#R960-25
#A-11008

Thermo Fisher Scientific

#13-2500

US Biomax

SO801b

Chemicals, Peptides, and Recombinant Proteins
DMEM
Life Technologies
Glucose-free DMEM
Life Technologies
Glucose-free and glutamine-free DMEM
Life Technologies
L-Glutamine
Life Technologies
Sodium Pyruvate
Life Technologies
Horse serum
Life Technologies
Standard FBS
Gemini
Dialyzed FBS
Gemini
HSMM cell growth media (SkGM-2 BulletKit) Lonza
[1,2-13C]glucose
Sigma-Aldrich
[3-13C]sodium pyruvate
Sigma-Aldrich
D-(+)-Glucose
Sigma-Aldrich
D-(+)-Galactose
Sigma-Aldrich
D-fructose 1,6-bisphosphate trisodium salt Sigma-Aldrich
hydrate
Perchloric acid, 70%
Sigma-Aldrich
Polybrene
Sigma-Aldrich
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11965-084
11966-025
A1443001
25030-081
11360-070
16050-122
900-108
100-108
CC-3245
453188
490733
G8270
G0750
F6803
311421
107689

Doxycycline hydrochloride
2-Hydroxyethyl agarose
Bovine serum albumin
MitoSox
Hoechst
MitoTracker Green FM
Propidium Iodide
ProLong Diamond Antifade Mountant with
DAPI
Halt Protease and Phosphatase Inhibitor
Cocktail
FuGENE 6 Transfection Reagent
Seahorse XFe96 FluxPaks
Seahorse XF Base Medium
Matrigel matrix
Glutathione Sepharose 4B resin
Doxycycline diet - Sterile
Control diet - Sterile
Critical Commercial Assays
Seahorse XF Cell Mito Stress Test Kit
Seahorse XF Glycolysis Stress Test Kit
Citrate Synthase Activity Assay Kit
FITC Annexin V Apoptosis Detection Kit
Deproteinizing Sample Preparation Kit
Fructose-6-Phosphate Fluorometric Assay
Kit
Nuclear
and
Cytoplasmic
Extraction
Reagents
ATP Determination Kit
Q5 Site-Directed Mutagenesis Kit
Wizard Genomic DNA Purification Kit
RNeasy Mini Kit
High-Capacity cDNA Reverse Transcription
Kit
Experimental Models: Cell Lines
293T
HT1080
C2C12
SW872
LPS224
LPS246
T449

Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Thermo Fisher Scientific
Thermo Fisher Scientific
Thermo Fisher Scientific
Thermo Fisher Scientific
Thermo Fisher Scientific

D3447
A4018
A7906
M36008
62249
M7514
P3566
P36962

Thermo Fisher Scientific

78445

Promega
Agilent
Agilent
Corning
GE Healthcare
Bio-Serv
Bio-Serv

E2691
102601-100
102353-100
356234
17075601
S3888
S4207

Agilent
Agilent
Abcam
BD Biosciences
BioVision
BioVision

103015-100
103020-100
ab119692
556547
K808
K689-100

Thermo Fisher Scientific

78833

Thermo Fisher Scientific
New England BioLabs
Promega
Qiagen
Applied Biosystems

A22066
E0554
A1120
74104
4368814

ATCC
ATCC
ATCC
ATCC
Core
Facilities,
MD
Anderson Cancer Center,
Houston, TX
Core
Facilities,
MD
Anderson Cancer Center,
Houston, TX
Established from a welldifferentiated liposarcoma

CRL-3216
CCL-121
CRL-1772
HTB-92
A gift from Dr.
Dina Lev
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A gift from Dr.
Dina Lev
CVCL_M807

T778

CVCL_M808

HSMM

Established from a welldifferentiated liposarcoma
Established from a welldifferentiated liposarcoma
Derived from UPS mouse
tumor
Lonza

Experimental Models: Organisms/Strains
NOD-scid IL2Rgammanull mice

The Jackson Laboratory

005557

Life Technologies
Life Technologies
Life Technologies
Life Technologies
Life Technologies
Life Technologies
Life Technologies
Life Technologies
Life Technologies
Life Technologies
Life Technologies
Life Technologies
Santa Cruz Biotechnology
Dharmacon
(Dickinson et al., 2013)

HS03928985_G1
HS02596873_S1
HS02596867_S1
HS02596864_G1
HS02596862_G1
Hs00273372_s1
Hs00602161_m1
Hs00153408_m1
Hs00153380_m1
Hs00230684_m1
Hs02339479_g1
Hs00795278_mH
sc-29226
D-001810-10-05

System Biosciences
Clontech
Addgene

CD510B-1
631847
85133
A gift from Dr.
Xiaolu Yang
A gift from Dr.
Xiaolu Yang
MHS6278211687897
MHS6278211689190
MHS6278202757860

T1000
KP250

Oligonucleotides
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CHAPTER 3 RESULTS
FBP2 is frequently lost in soft tissue sarcomas
To assess their potential role in regulating sarcoma cell glucose metabolism, we measured the
expression levels of three rate-limiting gluconeogenic enzymes, glucose-6-phosphatase catalytic
subunit (G6PC), phosphoenolpyruvate carboxykinase 1 (PCK1), and fructose-1,6-bisphosphatase
(FBP) using published microarray data from human STS (Barretina et al., 2010; Detwiller et al.,
2005). As previously reported (Mizunuma and Tashima, 1990; Tejwani, 1983), FBP1 is the
predominant isozyme in liver, kidney and small intestine (Figure 1A), whereas FBP2 expression
predominates in muscle (Figure 1B). Further analysis revealed that FBP2 mRNA levels are
significantly reduced in liposarcoma, fibrosarcoma, leiomyosarcoma, and UPS samples relative to
either normal skeletal muscle (Figure 2A) or adipose tissue (Figure 2B). Moreover, mouse UPS
tumors isolated from a previously described autochthonous “KP” (LSL-KrasG12D/+; Trp53fl/fl) model
(Kirsch et al., 2007; Mito et al., 2009) exhibited decreased FBP2 immunostaining relative to
adjacent skeletal muscle tissue (Figure 2C). FBP2 protein abundance was also decreased in a
variety of human sarcoma and mouse UPS cell lines, relative to mesenchymal stem cell (MSC) and
human skeletal muscle myoblast (HSMM) or mouse C2C12 myoblasts (Figure 2D). Analysis of a
representative human sarcoma tissue array showed undetectable FBP2 protein accumulation,
compared to normal mesenchymal tissue, in almost 100% of sarcoma tumors examined (n = 70,
Figure 3A-C). Even though FBP2 expression is widely repressed in STS, intertumoral heterogeneity
still results in different levels of repression among sarcoma samples, and a liposarcoma data set
(Gobble et al., 2011) revealed that lower FBP2 mRNA levels correlated with worse overall survival
in liposarcoma patients (Figure 3D). We concluded that FBP2 loss is a common feature in STS
subtypes and may contribute directly to tumorigenesis.

In contrast to FBP2, G6PC and PCK1 mRNA levels were similar in liposarcoma, fibrosarcoma,
leiomyosarcoma, and other sarcoma subtypes compared with normal skeletal muscle (Figure 4AC), and liposarcoma cell lines exhibited PCK1 and G6PC protein abundance comparable to control
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MSCs (Figure 4D). FBP1 was undetectable in tumors and sarcoma cell lines of diverse histological
subtypes or controls, including MSC and human skeletal muscle myoblast (HSMM) (Figure 4E-F).
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Figure 1. Differential tissue distribution of FBP1 and FBP2.
(A and B) FBP1 (A) and FBP2 (B) mRNA expression in multiple normal tissues and a variety of
human sarcoma samples. Fibrosarc, fibrosarcoma; Lipo.dediff, dedifferentiated liposarcoma;
Lipo.pleo, pleomorphic liposarcoma; Lipo.round, round cell liposarcoma; MFH, malignant fibrous
histiocytoma.
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Figure 2. FBP2 is severely downregulated in a variety of sarcomas.
(A and B) FBP2 mRNA expression from Oncomine analysis of the (A) Detwiller et al. and (B)
Barretina et al. sarcoma patient samples data set (Barretina et al., 2010; Detwiller et al., 2005).
Values are normalized to median-centered intensity and shown on a log2 scale. Abbreviations:
dediff. lipo., dedifferentiated liposarcoma; MFH, malignant fibrous histiocytoma; MFH/Pleo., UPS;
pleomorphic lipo., pleomorphic liposarcoma; RC lipo., round cell liposarcoma. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001; n.s., not significant.
(C) Representative immunohistochemical (IHC) staining of FBP2 in mouse UPS tumor and
surrounding muscle. Scale bars: 100 µm.
(D) Immunoblot analysis of FBP2 protein level in various human (left) and mouse (right) sarcoma
cell lines. MSC, HSMM and C2C12 served as normal control. MSC, mesenchymal stem cell; HSMM,
human skeletal muscle myoblast; (N), normoxia; (H) hypoxia; D-, differentiated; LMS,
leiomyosarcoma; RD, rhabdomyosarcoma; FS, fibrosarcoma. GAPDH served as loading control.
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Figure 3. FBP2 protein abundance is uniformly decreased in sarcoma patient samples.
(A) Representative IHC FBP2 staining in human muscle and sarcoma samples from human
sarcoma tissue array, including fibrous histiocytoma, liposarcoma, neurilemmoma, and
leiomyosarcoma. Scale bars: 100 µm.
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(B) Immunohistochemistry staining of a representative sarcoma microarray with FBP2 antibody. T,
sarcoma tumor tissues; N, normal counterparts. Red box indicates normal counterparts. The
sarcoma type of each sample is listed below.
(C) Quantification of IHC staining of 70 sarcomas and 10 normal tissues with FBP2 antibody from
(B).
(D) Kaplan–Meier curve of overall survival of liposarcoma patients from the Gobble et al. data set
(Gobble et al., 2011), segregated into the top 33% FBP2 expression (High FBP2, n = 32), middle
33% FBP2 expression (Medium FBP2, n = 32), and bottom FBP2 expression (Low FBP2, n = 32).
The p-value was calculated using a log-rank (Mantel–Cox) test.
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Figure 4. The expression of other gluconeogenic enzymes exhibit no consistent change in
sarcoma.
(A) Illustration of central carbon metabolism, including glycolysis, gluconeogenesis, pentose
phosphate pathway, and the TCA cycle. Enzymes controlling glycolysis (HK, hexokinase; PFK,
phosphofructokinase; PKM, pyruvate kinase type M) are highlighted in orange, while enzymes
controlling gluconeogenesis (G6PC, glucose-6-phosphatase catalytic subunit; FBP, fructose-1,6-
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bisphosphatase; PCK, phosphoenolpyruvate carboxykinase) are highlighted in green. G6P,
glucose-6-phosphate; F6P, fructose 6-phosphate; F-1,6-BP, fructose 1,6-bisphosphate; DHAP,
dihydroxyacetone phosphate; GAP, glyceraldehyde 3-phosphate; R5P, ribose 5-phosphate; X5P,
xylulose 5-phosphate; PEP, phosphoenolpyruvate; Pyr, pyruvate; Lac, lactate; Cit, citrate; aKG, aketoglutarate; Glu, glutamate; Mal, malate; Oac, oxaloacetate; Asp, aspartate.
(B and C) G6PC (B) and PCK1 (C) mRNA expression based on Oncomine analysis of the Detwiller
et al. sarcoma patient samples data set (Detwiller et al., 2005). Values are normalized to mediancentered intensity and shown on a log2 scale. Dediff. lipo., dedifferentiated liposarcoma; MFH,
Malignant Fibrous Histiocytoma; pleomorphic lipo., pleomorphic liposarcoma; RC lipo., round cell
liposarcoma.
(D) Immunoblot analysis of PCK1 and G6PC protein levels in various human sarcoma cell lines.
MSC, mesenchymal stem cells. MSCs served as normal control, while GAPDH served as a loading
control.
(E) FBP1 mRNA expression based on Oncomine analysis of the Detwiller et al. sarcoma patient
samples data set (Detwiller et al., 2005).
(F) Immunoblot analysis of FBP1 protein levels in various human sarcoma cell lines. MSC,
mesenchymal stem cell; hep, human primary hepatocyte. MSC served as normal control and Hep
served as positive control for FBP1 expression. GAPDH served as a loading control. * indicates
non-specific band.
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FBP2 Re-Expression Suppresses Sarcoma Growth
To investigate its functional effects in different STS subtypes, we expressed FBP2 ectopically in
human liposarcoma (LPS246, T1000, SW872), fibrosarcoma (HT1080), and mouse UPS (KP250)
cell lines to levels observed in control HSMM or C2C12 cells, respectively (Figure 5A-B). FBP2
significantly inhibited cell proliferation under either low serum (1% serum, 25 mM glucose) or low
glucose (10% serum, 5 mM glucose) conditions (Figures 6A-B), reminiscent of nutrient starved
tumor microenvironments, as well as replete culture conditions (Figures 6C). In addition, FBP2 reexpression in SW872, HT1080 and KP250 cells dramatically impaired anchorage-independent
growth in 3D soft agar colony assays (Figure 7).

We also exploited a doxycycline (dox)-inducible system to restore FBP2 expression in LPS246
cells (LPS246 TetO-FBP2) and identified dox concentrations that produced FBP2 protein in
LPS246 TetO-FBP2 cells comparable to control HSMM cells (Figure 8A). To further evaluate the
role of FBP2 in tumor growth and maintenance in vivo, NSG mice were injected subcutaneously
with LPS246 TetO-FBP2 cells and tumors allowed to grow to 100 mm3. Subsequent dox-induced
FBP2 expression decreased tumor growth (volume and mass) without affecting mouse body weight
(Figure 8B-E). FBP2 expression was maintained during dox treatment as shown by western blot
(Figure 8F) and immunohistochemistry (IHC) (Figure 8G). The FBP2-expressing tumor cohorts
exhibited decreased tumor cell proliferation as indicated by decreased phospho-histone H3 staining
(Figure 8H). These results demonstrate that FBP2 restoration inhibits the in vitro proliferation and
in vivo tumor growth of multiple STS cell types, including UPS, fibrosarcoma and liposarcoma.
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Figure 5. Re-expression of FBP2 in multiple sarcoma cell lines.
(A and B) Immunoblot showing FBP2 expression levels over lentiviral titration in LPS246, T1000,
SW872 and HT1080 cells compared to HSMM (A), and in KP250 cells compared to C2C12 (B).
GAPDH served as a loading control. Arrows indicate virus volumes used for all experiments.
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Figure 6. FBP2 re-expression inhibits sarcoma cell proliferation.
(A) Growth of LPS246, T1000, SW872, and KP250 cells in low serum medium (1% FBS), with or
without ectopic FBP2 expression.
(B) Growth of LPS246, T1000, and HT1080 cells in low glucose medium (glucose free DMEM
supplemented with 10% FBS and 5 mM glucose) with vector control of FBP2 expression.
(C) Growth of LPS246, SW872, and HT1080 cells in replete medium (10% FBS and 25 mM glucose)
with vector control of FBP2 expression.
n = 3, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Figure 7. FBP2 re-expression inhibits anchorage independent growth.
(A-C) Soft agar colony formation assay of SW872 (A), HT1080 (B), and KP250 (C) cells with or
without FBP2 expression. Representative pictures of colony size (left) and quantification of colony
number (right).
Error bars represent SD of three replicate wells for each condition. *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001.
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Figure 8. Dox-induced FBP2 expression suppresses sarcoma progression.
(A) Immunoblot showing FBP2 expression level with increased doxycycline concentration in
LPS246 cells compared to HSMM. GAPDH served as loading control. The arrow indicates dox
concentration used for all experiments.
(B) Tumor volume of LPS246 TetO-FBP2 liposarcoma xenografts with or without dox-induced
FBP2 expression (each group includes ten tumors from five mice). ****p < 0.0001.
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(C and D) LPS246 xenograft tumor weight (C) and body weight (D) with or without dox treatment
at time of euthanasia, measured in grams. ****p < 0.0001, n.s., not significant.
(E) Representative xenograft tumors in mice fed with vehicle or dox chow.
(F) FBP2 induction in xenograft tumors were validated by western blot. GAPDH served as loading
control.
(G) Representative immunohistochemistry image of FBP2 staining on LPS246 TetO-FBP2 tumor
sections. Scale bars: 100 µm. Arrows indicate nuclear staining of FBP2.
(H) Representative image (left) of immunofluorescent staining of phosphor-Histone 3 and
quantifications (right) in xenograft tumors with or without dox treatment. Five fields per slide were
quantified. Scale bars: 100 µm. Error bars represent SD of three experimental replicates. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001. n.s., not significant.
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FBP2 Re-Expression Inhibits Glycolysis
Glucose metabolism is balanced by catabolic glycolysis/oxidative phosphorylation (OXPHOS)
and anabolic gluconeogenesis/glycogen production. Since FBP2 is a rate-limiting enzyme in
gluconeogenesis, FBP2 re-expression is likely to antagonize glycolysis and therefore reduce
glucose uptake. We ectopically expressed FBP2 in five STS cell lines and examined glucose
metabolism. FBP2 significantly decreased glucose uptake and lactate secretion without affecting
glutamine uptake in LPS224, LPS246, T1000, HT1080, and KP250 cells cultured in 10 mM glucose
(Figure 9A-C). To further assess glycolytic pathway, we investigated the metabolic fate of [1,213

C]glucose, which produces glycolytic and TCA cycle intermediates containing two 13C atoms, as

well as intermediates containing one 13C atom from the pentose phosphate pathway (PPP) (Figure
10A). Analysis of culture media confirmed reduced [1,2-13C]glucose uptake and M1- and M2labeled
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C-lactate secretion in FBP2-expressing LPS246 cells (Figure 10B-C), indicating

decreased conversion of glucose to lactate. [1,2-13C]glucose releases its first carbon in the form of
CO2 to generate M1 species when catabolized through the oxidative portion of PPP (Lee et al.,
1998); therefore, PPP flux can be determined by the ratio of M1- to M2-labeled lactate. Interestingly,
we found that FBP2 re-expression reduced PPP flux (Figure 10D), which is important for the
synthesis of ribonucleotides and NADPH. The same cell extracts were further analyzed by GC-MS
to quantify M2 enrichment of glucose-derived TCA intermediates (citrate, a-ketoglutarate, fumarate,
and malate), as well as TCA cycle products (aspartate and glutamate). We observed decreased
M2 enrichment of four TCA intermediates (Figure 10E), as well as glutamate and aspartate (Figure
10F) in FBP2-expressing cells.

In addition, we employed an unbiased approach to determine relative abundance of
intermediates from glycolysis, serine metabolism and the TCA cycle in KP250 and HT1080 cells.
In both cell lines, ectopic FBP2 expression significantly reduced steady-state abundance of
metabolites in glycolysis (glucose-6-phosphate, pyruvate, lactate) (Figure 11A), serine metabolism
(serine and glycine) (Figure 11B) and the TCA cycle (citrate, a-ketoglutarate, fumarate, malate,
oxaloacetate) (Figure 11C). In contrast to these decreased metabolic intermediates in FBP2-
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expressing cells, we observed enrichment of metabolites in other pathways (Figure 11D), indicating
a global metabolic adaptation in FBP2-expressing cells. Together, these results indicate that FBP2
inhibits glycolysis, which further affects serine and TCA cycle metabolism.
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Figure 9. FBP2 restoration opposes glycolysis in multiple sarcoma cell lines.
(A-C) Glucose uptake (A), lactate secretion (B), and glutamine uptake (C) were assessed in
LPS224, LPS246, T1000, HT1080, and KP250 cells with or without FBP2 re-expression by YSI
bioanalyzer.
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Figure 10. FBP2 re-expression inhibits glycolysis, the pentose phosphate pathway and
glucose-derived TCA cycle.
(A) Carbon fate map showing the isotopomer distribution of indicated metabolites derived from [1,213

C]glucose. 13C atoms are depicted as filled circles. 13C atoms directly going through the glycolytic

pathway are colored in red, while 13C atoms going through the PPP and recycled back to glycolysis
are colored in blue.
(B and C) [1,2-13C]glucose consumption (B), M1 and M2 isotopomer distribution of lactate (C)
measured from culture medium of LPS246 cells expressing vector control or FBP2.
(D) Calculated PPP flux (relative to vector control) in LPS246 cells with or without FBP2 expression
based on the M1 to M2 13C-lactate ratio in cell extracts.
(E and F) M2 isotopomer distribution of indicated TCA metabolites (E) and amino acids (F) in
LPS246 cells with or without FBP2 re-expression, labelled with [1,2-13C]glucose. M2 enrichment
represents the mole per cent excess of M2 species above natural abundance. aKG, a-ketoglutarate.
Values represent mean ± SD of three experimental replicates. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 11. Ectopic FBP2 expression opposes glycolysis and the TCA cycle.
(A-C) Pan-metabolomic analysis of steady-state metabolites in KP250 cells (left) and HT1080 cells
(right) expressing vector control or FBP2. Relative abundance of metabolites in glycolysis (A),
serine metabolism (B) and TCA cycle (C) are shown.
(D) Representative examples of metabolites whose relative abundance is higher in KP250 cells
(left) or HT1080 cells (right) upon FBP2 restoration, compared to cells expressing control vector.
Error bars represent SD of three experimental replicates. *p < 0.05, **p < 0.01, ***p < 0.001, ****p
< 0.0001. n.s., not significant.
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Nuclear FBP2 Inhibits Mitochondrial Gene Expression
To investigate whether the growth inhibitory effect of FBP2 is dependent on its enzymatic activity,
we generated a catalytically inactive FBP2 mutant by replacing a glycine residue at position
260 with arginine (FBP2G260R) as previously described (Åsberg et al., 2010) (Figure 12A). Upon
wild-type FBP2 and FBP2G260R expression at comparable levels in LPS246 cells (Figure 12B),
FBP2G260R inhibited cell growth, although to a lesser extent than wild-type FBP2 (Figure 12C),
implying that FBP2 has catalytic activity-independent cellular functions.

Accumulating evidence demonstrates that multiple glycolytic enzymes exhibit nuclear
localization and interact with transcription factors to regulate gene expression, in addition to their
cytoplasmic roles (Huangyang and Simon, 2018). Interestingly, we observed strong nuclear
staining of FBP2 within xenograft tumor sections (Figure 13A), suggesting that FBP2 possesses
nuclear function. Specifically, immunofluorescence indicated overlap between endogenous FBP2
staining and DAPI staining in C2C12 cells (Figure 13B), and subcellular fractionation of HSMM and
C2C12 cells further indicated that FBP2 co-purifies with both nuclear and cytosolic fractions (Figure
13C). A nuclear localization sequence (NLS) (203KKKGK207) was previously identified in
FBP2(Gizak et al., 2009a; 2009b). By replacing four lysine residues in the NLS with alanine, we
generated a nucleus-excluded form of FBP2 without disrupting its catalytic activity (Figure 13D),
and FBP24KA expression in LPS246 cells decreased cell proliferation albeit, not as dramatically as
wild-type FBP2, suggesting that nuclear FBP2 contributes functionally to its growth inhibitory
properties (Figure 13E-F). Interestingly, [1,2-13C]glucose labeling in control or FBP24KA-expressing
cells determined that FBP24KA inhibits glucose uptake and lactate secretion (Figure 13G-H), but
less potent than wild-type FBP2 (Figure 10B-C). These results indicate that nuclear FBP2 is also
involved in suppressing glycolysis.

To gain further mechanistic insights into the function of nuclear FBP2, we compared the
transcriptomes of vehicle (n = 5) or dox-treated (n = 4) LPS246 TetO-FBP2 cells by RNA-seq. Gene
set enrichment analysis of FBP2-restored cells revealed reduced gene expression signatures for
E2F targets, MYC targets, the G2M checkpoint, and OXPHOS (Figure 14A), as well as increased
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expression signatures related to protein secretion, UV responses, and heme metabolism (Figure
14B). Ingenuity Pathway Analysis (IPA) also identified OXPHOS and mitochondrial dysfunction as
the primary differentially modulated pathways in FBP2-expressing cells, compared to controls
(Figure 14C). These functional categories contain genes encoding essential subunits of
mitochondrial complex I, III, IV and V of the electron transport chain and genes critical for
mitochondrial function (UCP2 and RHOT2) (Figure 14D). We confirmed differential expression of
several genes involved in OXPHOS (MT-ND1, MT-MYB, MT-CO1 and MT-ATP6) by qRT-PCR
analysis and found that FBP2, but not FBP24KA, significantly decreased their expression (Figure
15A). Intriguingly, catalytically inactive FBP2G260R downregulated mitochondrial gene expression to
a similar level as wild-type FBP2 (Figure 15B). Taken together, these data suggest that nuclear
FBP2 is required for inhibiting OXPHOS in an enzymatic activity-independent manner.
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Figure 12. Catalytically inactive FBP2G260R suppresses sarcoma cell growth.
(A) Enzymatic activity in 293T cells expressing vector, wild-type FBP2 and FBP2G260R.
(B) Protein levels of ectopically expressed FBP2 and FBP2G260R in LPS246 cells. GAPDH was used
as a loading control.
(C) Growth of vector control, FBP2- or FBP2G260R-expressing LPS246 cells grown in 1% serum
medium.
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Figure 13. Nuclear FBP2 is able to inhibit sarcoma cell proliferation and glycolysis.
(A) Immunofluorescent staining of mouse myoblast C2C12 cells with FBP2 antibody. Asterisks
indicate representative sites with nuclear FBP2. DAPI is a fluorescent nuclear dye.
(B) FBP2 protein levels detected in cytosolic and nuclear fractions of C2C12 and HSMM. HSP90,
a cytosolic protein, and HDAC1, a nuclear protein, reflect the purity of respective subcellular
fractionations.
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(C) Western blot analysis of V5-tagged FBP2 or FBP24KA (4 lysines in nuclear localization sequence
were substituted with alanine) in the cytosolic and nuclear fractions of transfected LPS246 cells.
(D) Enzymatic activity in 293T cells expressing control vector, wild-type FBP2 and FBP24KA.
(E) Protein levels of ectopically expressed FBP2 and FBP24KA mutant in LPS246 cells. GAPDH
serves as a loading control.
(F) Growth of vector control, FBP2- or FBP24KA-expressing LPS246 cells in 1% serum medium.
(G and H) [1,2-13C]glucose consumption (G), M1 and M2 isotopomer distribution of lactate (H)
measured from culture medium of LPS246 cells expressing vector control or FBP2.

49

Figure 14. RNA-seq analyses of transcriptome between vehicle or dox treated LPS246 TetOFBP2 cells.
(A and B) GSEA comparing vehicle-treated (n = 5) and dox-treated (n = 4) LPS246 TetO-FBP2
cells. The 50-gene “Hallmark signatures” set from MsigDB was queried. Top 10 gene sets
downregulated (A) or upregulated (B) in dox-treated groups are shown with the normalized
enrichment score (NES). Relevant gene sets are highlighted with red.
(C) Differentially expressed genes were analyzed using ingenuity pathway analysis (IPA) software.
Top 10 relevant and significant biological pathways were identified according to p-value from
Fisher’s exact test.
(D) Heatmap showing the relative expression of OXPHOS genes and mitochondrial dysfunction
pathway from IPA. Expression signals are depicted using pseudocoloring, in which expression for
each gene is shown as high (red) or low (blue).
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Figure 15. Nuclear FBP2 inhibits mitochondrial gene expression in a catalytic activityindependent manner.
(A) qRT-PCR analysis of MT-ND1, MT-CYB, MT-CO1, and MT-ATP6 in LPS246 cells constitutively
expressing TetO-FBP2 or Tet-FBP24KA, treated with vehicle or dox.
(B) qRT-PCR analysis of MT-ND1, MT-CYB, MT-CO1, and MT-ATP6 in LPS246 cells constitutively
expressing vector, FBP2 or FBP2G260R.
Error bars represent SD of three experimental replicates. *p < 0.05, **p < 0.01, ***p < 0.001, ****p
< 0.0001. n.s., not significant.
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Nuclear FBP2 Impairs Mitochondrial Biogenesis
To determine whether reduced transcription of OXPHOS genes in FBP2-expressing cells
correlated with decreased mitochondrial biogenesis, we first measured mitochondrial DNA content
by using real-time quantitative PCR. Mitochondrial to nuclear DNA ratios were dramatically
decreased in FBP2-expressing LPS246 cells (Figure 16A), and flow cytometric analysis of cells
stained with MitoTracker further revealed that FBP2 induction reduced mitochondrial mass (Figure
16B). Similarly, we observed a dramatic decrease in citrate synthase activity after restoring
expression of FBP2 in LPS246 cells (Figure 16C). Decreased mitochondrial biogenesis in FBP2expressing LPS246 cells was further confirmed by transmission electron microscopy, indicated by
reduced number of mitochondria and swollen mitochondria with disorganized cristae (Figure 16D).
Consistently, LPS246 xenograft sections exhibited reduced staining of Vdac (voltage-dependent
anion channel) and Tomm20 (a constitutively expressed mitochondrial protein) in dox-treated
tumors, supporting decreased mitochondrial mass caused by FBP2 expression (Figure 16E). As
doxycyline has been reported to interfere with mammalian protein synthesis and disrupt
mitochondrial proteostasis and function (Moullan et al., 2015), we confirmed that mtDNA content,
MitoTracker staining, and citrate synthase activity were comparable in both vehicle and dox-treated
LPS246 TetO-FBP24KA cells (Figure 16A-C). Collectively, these data demonstrate that nuclear
FBP2 inhibits mitochondrial biogenesis in LPS246 cells.
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Figure 16. Nuclear FBP2 impairs mitochondrial biogenesis.
(A) qPCR analysis of mitochondrial (MT-ND1) versus nuclear (b-globin) DNA content in indicated
cells (three experimental replicates).
(B) LPS246 TetO-FBP2 cells and TetO-FBP24KA cells stained with MitoTracker Green FM probe.
Flow cytometry plots (left) show the fluorescence intensity corresponding to mitochondrial mass.
Histograms (right) show the quantification (three experimental replicates).
(C) Citrate synthase activity measured in indicated cells (three experimental replicates).
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(D) Ultrastructural analysis of mitochondria in LPS246 Teto-FBP2 cells using transmission electron
microscopy. Scale bars: 1 µm. Quantification of the number of mitochondria per cell in the imaged
section (vehicle treated, n = 10 cells; dox treated, n = 10 cells).
(E) Immunohistochemical staining for expression of voltage-dependent anion channel (Vdac) and
Tomm20 on sections from LPS246 TetO-FBP2 xenografts treated with vehicle or dox. Five fields
per slide were quantified. Scale bars: 100 µm.
Data are represented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s., not
significant.
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FBP2 Suppresses Mitochondrial Respiration and the TCA Cycle
The effects of FBP2 expression on mitochondrial OXPHOS activity were investigated by culturing
LPS246 cells in glucose-free medium containing 5 mM galactose, which cannot be fermented,
requiring cells to rely on mitochondrial metabolism to generate sufficient ATP for survival (Rossignol
et al., 2004). We observed increased apoptosis in dox-treated LPS246 TetO-FBP2 cells cultured
in galactose medium (Figure 17A-B) compared to vehicle-treated cells, indicating that mitochondrial
OXPHOS is critically impaired upon FBP2 induction. Furthermore, oxygen consumption rates (OCR)
and ATP production were lower in FBP2-expressing LPS246 cells compared to controls (Figure
17C-D, I). In contrast, FBP24KA expression had no effect on OCR in LPS246 cells (Figure 17E-F).
Loss of ATP-generating capacity stimulated glycolytic compensation in both LPS246 TetO-FBP2
and TetO-FBP24KA cells, as indicated by extracellular acidification rate (ECAR) (Figure 17G-H).
Interestingly, ECAR was lower in both FBP2- and FBP24KA-expressing LPS246 cells than control
cells (Figure 17G-H), indicating inhibition of glycolysis by each protein. These results are consistent
with our previous conclusion that FBP2 suppresses glucose uptake and lactate secretion (Figure
9-11). In active mitochondria, a small percentage of electrons are prematurely leaked to O2 from
complex I and/or complex III, resulting in the formation of reactive oxygen species (ROS)
(Chatterjee et al., 2011). As expected, reduced OCRs observed in FBP2-expressing LPS246 cells
correlated with a substantial decrease in ROS levels; whereas FBP24KA had no effect on ROS
accumulation (Figure 17J).

To assess the effects of FBP2 expression on TCA cycle metabolite levels, we performed isotope
tracing experiments by labeling vehicle- or dox-treated LPS246 TetO-FBP2 cells with [313

C]pyruvate. Labeled pyruvate is converted to acetyl-CoA by mitochondrial pyruvate

dehydrogenase, which then combines with oxaloacetate to produce M1-labeled citrate. When
acetyl-CoA is abundant, pyruvate decarboxylase can also generate M1-labeled oxaloacetate,
which then incorporates M1-labeled acetyl-CoA to produce M2-labeled citrate (Figure 18A). We
observed decreased M1 and M2 enrichment of three TCA intermediates (citrate, fumarate and
malate), as well as glutamic acid and aspartic acid (Figure 18B-E) in FBP2-expressing cells. In
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contrast, ectopic FBP24KA expression had no effect on M1 and M2 enrichment of TCA intermediates
and products compared with control cells (Figure 18F-I), further indicating that it is nuclear FBP2
that restrains mitochondrial function and metabolism.
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Figure 17. FBP2 suppresses mitochondrial respiration.
(A) LPS246 cells cultured in 5 mM glucose and 5 mM galactose medium. Apoptotic cells measured
through Annexin V/PI staining followed by flow cytometry.
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(B) Indicated cells were cultured in 5 mM glucose and 5 mM galactose medium. Flow cytometry
plots of annexin V/PI staining of indicated cells.
(C-F) Relative oxygen consumption rate normalized to protein abundance in LPS246 TetO-FBP2
cells (C) or LPS246 TetO-FBP24KA cells (E) treated with vehicle or dox. Histogram showing basal,
ATP-linked and maximal respiration in LPS246 TetO-FBP2 cells (D) or LPS246 TetO-FBP24KA cells
(F) treated with vehicle or dox. Data are presented as mean ± SD of three reading cycles of n = 9
wells pooled from three independent experiments.
(G and H) Relative extracellular acidification rate (ECAR) normalized to protein abundance in
LPS246 TetO-FBP2 cells (G) or LPS246 TetO-FBP24KA cells (H) treated with vehicle or dox. Data
are presented as mean ± SD of three reading cycles of n = 9 wells pooled from three independent
experiments.
(I) ATP production was measured in indicated cells.
(J) Fluorescence intensity of MitoSox analyzed by flow cytometry. Flow cytometry plots (left) show
the fluorescence intensity. Histograms (right) display their quantification (three experimental
replicates). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s., not significant.
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Figure 18. Nuclear FBP2 inhibits the TCA cycle in LPS246 cells.
(A) Carbon fate map showing the isotopomer distribution of indicated metabolites derived from [313

C]pyruvate. 13C atoms are depicted as filled circles.

13

C atoms directly going through the acetyl-

CoA are colored in red, while 13C atoms going through oxaloacetate and combined with acety-CoA
to generate citrate are colored in blue.
(B-E) M1 isotopomer distribution of indicated TCA metabolites (A) and amino acids (B), and M2
isotopomer distribution of indicated TCA metabolites (C) and amino acids (D) in LPS246 TetOFBP2 cells with vehicle or dox treatment, labelled with [3-13C]pyruvate.
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(F-I) M1 isotopomer distribution of indicated TCA metabolites (F) and amino acids (G), and M2
isotopomer distribution of indicated TCA metabolites (H) and amino acids (I) in LPS246 TetOFBP24KA cells with vehicle or dox treatment, labelled with [3-13C]pyruvate.
Error bars represent SD of three experimental replicates except in B and C. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001. n.s., not significant.
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FBP2 Transcriptionally Represses Mitochondrial Biogenesis
Mitochondrial biogenesis and function are controlled by a set of nuclearly-encoded transcription
factors, including PPAR-γ coactivators (PGC-1a), nuclear respiratory factor 1 (NRF1), and
mitochondrial transcription factor A (TFAM) (Scarpulla, 2012). As nuclear FBP2 regulates
mitochondrial function, we hypothesized that FBP2 dampens mitochondrial biogenesis through
inhibiting one or more of these nuclear regulators. Quantitative RT-PCR analyses revealed
significant downregulation of NRF1 and TFAM expression upon FBP2 restoration (Figure 19A).
Ectopic expression of TFAM or NRF1 reversed the suppression of target genes associated with
OXPHOS (MT-ND1, MT-CYB, MT-CO1 and MT-ATP) (Figure 19B-C, Figure 20A-B), and partially
restored mitochondrial mass (Figure 19D, Figure 20C). Moreover, ectopic TFAM or NRF1
expression partially reversed cell apoptosis (Figure 19E, Figure 20D) and proliferation (Figure 19F,
Figure 20E) in dox-treated LPS246 TetO-FBP2 cells.

To elucidate the molecular mechanisms whereby FBP2 alters the expression of nuclear
transcription factors associated with mitochondrial biogenesis, we examined the top differentially
expressed pathways based on RNA-seq data and identified Myc target genes as one of the top
downregulated gene sets (Figure 14A). Previous studies have demonstrated that c-Myc regulates
mitochondrial biogenesis and gene expression (Lee et al., 2017; Scarpulla, 2008); for example, cMyc induces NRF1 target genes by binding to a canonical NRF1 binding site, leading to the
sensitization of cells to apoptosis (Morrish et al., 2003). In addition, c-Myc potentiates mitochondrial
biogenesis through induction of TFAM and other nuclear-encoded mitochondrial genes (Li et al.,
2005). To ascertain that FBP2 diminishes c-Myc transcriptional activity, we measured c-Myc
luciferase-reporter intensity and found FBP2 decreased c-Myc functionality (Figure 21A). Transcript
levels of c-Myc target genes (CCND2, eIF2A, NPM1, PSAT1) were also decreased in FBP2expressing cells (Figure 21B). To determine whether FBP2 represses mitochondrial biogenesis in
a predominantly c-Myc dependent manner, we assessed the expression of mitochondrial genes
(MT-ND1, MT-CO1 and MT-ATP6) in the presence and absence of c-Myc using RNA interference.
Interestingly, dox-induced FBP2 expression or sic-Myc resulted in comparable repression of
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mitochondrial gene transcription (Figure 21C-D), and combined FBP2 expression and sic-Myc
showed no additive effects on gene expression. MitoTracker staining indicated a slight but
perceptible decrease in mitochondrial mass in cells with combined dox and sic-Myc treatment,
relative to cells with either treatment alone (Figure 21E). We conclude that FBP2’s inhibition of
mitochondrial biogenesis is largely, but not entirely dependent on the c-Myc pathway.

c-Myc has been reported to bind TFAM in the region of amplicons 1 and 2, approximately 900
bp upstream of the transcription start site (Figure 22A), thereby stimulating TFAM expression (Li et
al., 2005). Remarkably, chromatin immunoprecipitation (ChIP) analyses indicated that FBP2
protein was enriched at amplicon 1, which contains a 5’-CACGTG-3’ c-Myc binding site, but not at
amplicon 2, which contains a Myc/Max 5’-GCG-3’ half site (Figure 22B). As expected, nucleusexcluded FBP24KA was not detected at either amplicon (Figure 22B). Importantly, ChIP-reChIP
analyses revealed co-localization of c-Myc and FBP2 proteins at TFAM promoter amplicon 1
(Figure 22C). We also demonstrated the association of epitope-tagged FBP2 or FBP24KA and
endogenous c-Myc by co-immunoprecipitations in LPS246 cell lysates (Figure 22D), suggesting
their physical interaction can occur in both the nucleus and cytosol (albeit at lower levels). Finally,
GST pull-down assays of bacterially expressed proteins further revealed that FBP2 directly binds
to c-Myc (Figure 22E). Collectively, these results indicate that FBP2 inhibits c-Myc transcriptional
activation of TFAM, by direct physical association at its promoter.
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Figure 19. Ectopic expression of TFAM partially rescued mitochondrial biogenesis.
(A) qRT–PCR analysis of NRF1 and TFAM in vehicle treated or dox-treated LPS246 TetO-FBP2
cells.
(B) Immunoblot analysis for ectopic expression of vector control or TFAM in LPS246 TetO-FBP2
cells.
(C) qRT-PCR analysis of MT-ND1, MT-CYB, MT-CO1, and MT-ATP6 in indicated cells.
(D) LPS246 TetO-FBP2 cells with or without TFAM expression stained with MitoTracker Green FM
probe. Fluorescence intensity corresponding to mitochondrial mass is shown in histograms.
(E) Indicated cells cultured in 5 mM glucose and 5 mM galactose medium, where apoptotic cells
were measured through Annexin V/PI staining followed by flow cytometry.
(F) Growth of indicated cells in low serum medium (1% FBS).
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Figure 20. NRF1 partially rescues FBP2-mediated inhibition of mitochondrial biogenesis.
(A) Immunoblot analysis for ectopic expression of vector control or NRF1 in LPS246 TetO-FBP2
cells.
(B) qRT-PCR analysis of MT-ND1, MT-CYB, and MT-CO1 in indicated cells.
(C) LPS246 TetO-FBP2 cells with or without NRF1 expression were stained with MitoTracker
Green FM probe. Fluorescence intensity corresponding to mitochondrial mass is shown in
histogram.
(D) Indicated cells were cultured in 5 mM glucose and 5 mM galactose medium. Apoptotic cells
were measured through Annexin V/PI staining followed by flow cytometry.
(E) Growth of indicated cells in low serum medium (1% FBS).
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Figure 21. FBP2 inhibits mitochondrial biogenesis in a c-Myc dependent manner.
(A) c-Myc reporter activity measured in LPS246 TetO-FBP2/FBP24KA cells transfected with
Myc/Max luciferase reporter, in the presence of vehicle or dox. Transfection efficiencies were
normalized to co-transfected pRenilla-luciferase.
(B) qRT-PCR analysis of c-Myc target genes (CCND2, eIF2A, NPM1, PSAT1) in indicated cells.
(C and D) qRT-PCR analysis of c-Myc (C) and MT-ND1, MT-CO1 and MT-ATP6 (D) in LPS246
TetO-FBP2 cells under four conditions (+ Veh, siControl; + Dox, siControl; + Veh, sic-Myc; + Dox,
sic-Myc).
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(E) LPS246 TetO-FBP2 cells treated with four conditions stained with MitoTracker Green FM probe.
Histogram shows the quantification of fluorescence intensity corresponding to mitochondrial mass.
Data are represented as mean ± SD (three experimental replicates) *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001. n.s., not significant.
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Figure 22. FBP2 suppresses TFAM expression by co-localizing with c-Myc at the promoter
region of TFAM.
(A) Diagram of 2 kb upstream of exon 1 to exon 2 of human TFAM. Exons are represented by
green boxes. The E box in amplicon 1 is illustrated. Horizontal bars labeled Neg, 1, 2 indicate the
regions amplified for ChIP analysis.
(B) ChIP assays evaluating FBP2 association with chromatin at a c-Myc binding site in TFAM
promoter (amplicon 1 and 2), or to a site negative for c-Myc binding (amplicon Neg). IgG, isotypematched immunoglobulin G; V5, V5-tagged FBP2.
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(C) ChIP-reChIP analysis examining the co-localization of c-Myc and FBP2 at amplicon 1 and 2 at
TFAM promoters.
(D) V5 tagged FBP2 or FBP24KA-expressing LPS246 cell lysates were immunoprecipitated with IgG,
or V5 antibody and blotted for endogenous c-Myc. IP, immunoprecipitate.
(E) GST pull-down analysis between recombinant His-FBP2 and recombinant GST or GST-tagged
c-Myc and blotted using FBP2 antibody.
Data are represented as standard error of the mean (three technical replicates from a
representative experiment). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s., not significant.
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Discussion
Soft-tissue sarcomas (STS) are a complex set of mesenchymal malignancies, compromising
more than 70 subtypes (Fletcher, 2014). Despite rapid advances in the molecular analysis of
individual subtypes, the heterogeneous nature of sarcomas limits the efficacy of targeted therapies
(Cancer Genome Atlas Research Network, 2017; Linch et al., 2014), emphasizing the need to
identify therapeutic vulnerabilities common to multiple STS subtypes. Although a diverse spectrum
of oncogenic mutations has been recently described for in STS (Barretina et al., 2010; Cancer
Genome Atlas Research Network, 2017; Eisinger-Mathason et al., 2015; Frith et al., 2013;
Nakazawa et al., 2016a), it is increasingly clear that all tumors must adapt cell metabolism to
support growth. Whereas metabolic reprogramming in STS has long been observed (Shaw et al.,
1988), how this influences sarcoma growth is unclear. In the current study, we demonstrate that
the gluconeogenic enzyme FBP2 is uniformly depleted in multiple sarcoma subtypes. Restoring
FBP2 expression in sarcoma cells dramatically inhibited tumor cell growth both in vitro and in vivo
(Figure 6-8), suggesting that FBP2 has tumor suppressive activities in sarcomas. We further
discovered that FBP2 exhibits two distinct tumor-suppressive functions that depend on its
subcellular localization. These results identify a specific metabolic adaptation as a common feature
of STS and could help inform therapeutic strategies.

Tumor cells are typified by enhanced glycolysis, as a means of generating ATP and providing
building blocks for macromolecule biosynthesis, sometimes known as the “Warburg effect” (Vander
Heiden and DeBerardinis, 2017; Warburg, 1956). Reprogrammed glucose metabolism is induced
by multiple mechanisms, such as the deregulation of oncoproteins and tumor suppressors (Hay,
2016). Previous studies uncovered frequently mutated genes in STS, including TP53, NF1 and
PIK3CA (Barretina et al., 2010; Frith et al., 2013), further confirmed by recent large-scale analyses
of 206 adult soft tissue sarcomas representing 6 major subtypes using multi-platform molecular
profiling (Cancer Genome Atlas Research Network, 2017). The p53 protein is involved in regulation
of glucose metabolism by promoting OXPHOS and dampening glycolysis (Humpton and Vousden,
2016). Furthermore, PIK3CA mutations, among the most frequent somatic mutations found in STS
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along with gain of function mutations in c-KIT and PDGFRa, are implicated in activation of the
AKT/mTOR pathway (Fruman et al., 2017; Yuan and Cantley, 2008), stimulating a shift towards
aerobic glycolysis (Lien et al., 2016). We show here that FBP2 loss also underlies increased
glycolytic activity observed in sarcomas, as FBP2 re-expression inhibits glucose uptake and lactate
secretion in distinct sarcoma cell lines. We also observed decreased glycolytic intermediates for
biosynthesis in FBP2-expressing cells, such as glucose-6-phosphate, serine and glycine,
consistent with previous speculation that FBP2 participates in the regulation of glycolysis
(Newsholme and Crabtree, 1970). Furthermore, FBP2 restoration reduces PPP activity needed for
ribonucleotide production and reducing equivalents in the form of NADPH.

Increasing evidence shows that multiple essential glycolytic/gluconeogenic enzymes localize to
the nucleus and influence gene transcriptional regulation (Boukouris et al., 2016; Huangyang and
Simon, 2018). We suggest a model in which metabolic enzymes transduce signals from growth
factors, nutrient and oxygen availability, and external stress to modulate gene expression. We
reported previously that nuclear FBP1 functions as a transcriptional corepressor to inhibit HIF-1a
and its downstream targets, including genes associated with glucose metabolism (GLUT1, LDHA,
and PDK1), therefore decreasing glycolytic phenotypes and enhancing glutamine uptake in tumor
cells (Li et al., 2014). FBP2 has been previously shown to reside in nuclei of myogenic progenitor
cells, cardiomyocytes and smooth muscle cells (Gizak and Dzugaj, 2003; Gizak et al., 2005; 2006),
although its nuclear function was unclear. We determined that FBP2 nuclear activity suppresses
sarcoma cell growth by inhibiting mitochondrial biogenesis and OXPHOS in a catalytic activityindependent manner, at least in part by repressing the expression of critical transcription factors
NRF1 and TFAM. Of note, nuclear FBP2 also plays a role in suppressing glycolysis, as nucleusexcluded FBP24KA exhibited less potent inhibition of glucose uptake and lactate secretion than wildtype FBP2, as indicated by [1,2-13C]glucose labeling experiments (e.g. 26% decrease in glucose
consumption by FBP2 versus 14% by FBP24KA, Figure 10B and Figure 13G). We can account for
this based on decreased expression of c-Myc target genes in FBP2-expressing cells from RNAseq (Figure 4G). c-Myc regulates virtually all genes involved in glycolysis (Dang et al., 2006),
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including the essential glycolytic enzymes LDHA, PDK1 and ENO1, consistent with our observation
that nuclear FBP2 also contributes to changes in glucose catabolism.

It’s noteworthy that even though FBP1 and FBP2 have different tissue distributions, they share
many functional similarities due to 77% sequence homology. For example, enforced expression of
FBP1 in sarcoma cells or FBP2 in renal cancer cells suppresses tumor cell proliferation (Figure
23A-D). In addition, we showed that c-Myc transcriptional activity can also be suppressed by FBP1
in sarcoma cells (Figure 23E). Interestingly, in contrast to c-Myc, the effect of FBP1 and FBP2 on
HIF signaling is tissue type-dependent. We consistently observed increased HRE luciferase activity
upon FBP1/FBP2 expression in different sarcoma cell lines (Figure 23F-J). However, both proteins
inhibit HIF transcriptional output in renal cancer cells. These results are in line with our previous
findings that HIF2a is actually a tumor suppressor in soft tissue sarcoma, unlike kidney cancer
(Nakazawa et al., 2016a) and increased HIF activity might also be involved in FBP2-mediated
growth inhibition.

Recent isotope tracing analysis of human ccRCC confirmed enhanced glycolysis and
suppressed glucose oxidation by the TCA cycle in these tumors (Courtney et al., 2018), likely due
to HIF stabilization caused by frequent von Hippel-Lindau (VHL) mutations (Nickerson et al., 2008).
However, sarcoma cells exhibited more active mitochondrial metabolism than ccRCC, as the
incorporation rate of 13C from [1,2-13C]glucose into TCA cycle intermediates is faster (Figure 10EF; see (Li et al., 2014)), suggesting that mitochondrial activity is critical for sarcoma progression.
While earlier studies emphasized the importance of glycolysis, mitochondrial biosynthesis,
bioenergetics, and signaling are also essential for tumorigenesis (Weinberg and Chandel, 2015).
Intermediates from the TCA cycle, such as citrate, aspartate and glutamate, are precursors for
macromolecule synthesis (lipid and nucleotides) to support biomass accumulation (Birsoy et al.,
2015; Faubert et al., 2017; Hosios et al., 2016; Sellers et al., 2015). In addition, the mitochondrial
ETC produces ROS via oxidative metabolism. Elevated ROS levels activate signaling pathways to
promote cell proliferation and tumor progression (Schieber and Chandel, 2014). By inhibiting
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mitochondrial function, FBP2 reduces the abundance of TCA cycle intermediates, ATP, and ROS,
therefore inhibiting cell growth.

A key observation is that FBP2 co-localizes with the c-Myc oncogene at the TFAM promoter,
suggesting that FBP2 acts as a nuclear c-Myc transcriptional corepressor. c-Myc affects a large
spectrum of genes involved in mitochondrial function (Kim and Dang, 2005) and directly activates
TFAM expression. Given the multitude of biological processes c-Myc regulates, the precise
mechanisms whereby FBP2 specifically targets c-Myc-induced mitochondrial biogenesis remain to
be elucidated. Presumably, additional factors are required to regulate c-Myc driven targets
associated with mitochondrial functions. Another nuclearly-encoded transcription factor, NRF1 is
key to mitochondrial biogenesis and also an upstream regulator of TFAM (Kelly and Scarpulla,
2004). Decreased NRF1 expression in FBP2-expressing cells further explains reduced TFAM
activity in this context.

Interestingly, FBP2 has been reported to translocate from the nucleus to the cytosol during
myoblast differentiation (Gizak et al., 2006), which corresponds to a shift from a highly glycolytic
state to increased OXPHOS needed in fully developed muscle cells (Remels et al., 2010). We
suggest that FBP2 is restricted to the nucleus in muscle progenitors to transcriptionally suppress
mitochondrial biogenesis and OXPHOS, as undifferentiated cells frequently favor glycolytic
metabolism. At the onset of differentiation, FBP2 exits the nucleus and functions as a
gluconeogenic/glycogen producing enzyme to antagonize glycolysis in the cytosol. How FBP2
translocation is regulated and whether subcellular shuttling of FBP2 contributes to muscle
differentiation are unclear, and remain part of our future studies. It will also be important to evaluate
the role of FBP2 in adipogenic differentiation, another lineage derived from mesenchymal stem
cells.

In summary, our findings demonstrate a role for FBP2 in suppressing sarcoma progression and
further establish dual tumor-suppressive functions of FBP, including promoting gluconeogenesis
and inhibiting mitochondrial biogenesis by inhibiting c-Myc transcriptional activity (Figure 24).
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Figure 23. Functional similarity of FBP1 and FBP2 in different tumor type.
(A and B) Growth of RCC10 cells in low serum medium (1% FBS) (A) or low glucose medium (5
mM glucose) (B), with or without ectopic FBP2 expression.
(C and D) Growth of LPS246 cells in low serum medium (1% FBS) (C) or low glucose medium (5
mM glucose) (D), with or without ectopic FBP1 expression.
(E) c-Myc reporter activity measured in vector-, FBP1- or FBP2-expressing LPS246 cells
transfected with Myc/Max luciferase reporter. Transfection efficiencies were normalized to cotransfected pRenilla-luciferase.
(F-J) HRE reporter activity measured in vector-, FBP1- or FBP2-expressing RCC10 cells (F),
LPS224 cells (G), LPS246 cells (H), T778 cells (I), and HT1080 cells (J) transfected with Myc/Max
luciferase reporter. Transfection efficiencies were normalized to co-transfected pRenilla-luciferase.
n = 3, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Figure 24. Model depicting the metabolic status, transcription activity and mitochondrial
change of sarcoma cells upon FBP2 re-expression. The cytosolic FBP2 inhibits glycolysis and
following TCA cycle. The nuclear FBP2 restrains mitochondrial function by co-localizing with c-Myc
at the promoter region of TFAM, a nuclearly encoded transcription factor that is crucial for
mitochondrial biogenesis.
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CHAPTER 4 CONCLUSIONS
Over the past decade, study of cellular metabolism has been rigorously revisited, especially in
the field of cancer research, revealing new insights that significantly expand our understanding of
cancer. However, general metabolic alterations in soft tissue sarcomas are largely understudied
and there appear to be at least some common phenotypes among diverse sarcoma subtypes. The
extent of soft tissue sarcoma heterogeneity has led to questions about the usefulness of targeting
individual signaling molecules as a practical therapeutic strategy. As described in Chapter 1,
abnormal glucose metabolism, which has long been observed in sarcoma patients, could be
exploited as a potential therapeutic target. In order to expand our understanding of increased
glucose catabolism in sarcoma patients, my thesis aims to investigate the impact of FBP2 loss on
sarcoma progression by depicting its canonical enzymatic activity in gluconeogenesis and noncanonical functions in the nucleus. I determined that FBP2 exhibits two distinct tumor-suppressive
functions depending on its subcellular localization.

In Chapter 3, I demonstrated that FBP2 re-expression in sarcoma cells significantly suppresses
tumor cell growth both in vitro and in vivo, indicating that FBP2 acts as a tumor suppressor in
sarcomas. I further revealed that FBP2 restoration significantly inhibits glycolysis, the TCA cycle
and the pentose phosphate pathway. However, decreased glycolytic activity is not only based on
FBP2’s catalytic activity, as ectopic expression of nuclear excluded FBP24KA exhibited less potent
inhibition of glycolysis. These results indicate that nuclear FBP2 is also implicated in regulating
glucose metabolism.

Interestingly, accumulating evidence indicates that various metabolic enzymes have surprisingly
novel activities outside of their established metabolic roles, including regulating gene expression,
cell cycle progression, and apoptosis (Huangyang and Simon, 2018). Many of these new functions
are activated in response to growth factor signaling, nutrient and oxygen availability, and external
stress. As such, multifaceted enzymes directly link metabolism to transcription, engaging diverse
physiological and pathological processes to maintain cell homeostasis. We compared the
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transcriptome between control and FBP2-expressing LPS246 cells, and determined that
mitochondrial dysfunction is the primary differentially expressed functional category. We further
confirmed that nuclear FBP2 mediates the suppression of mitochondrial function by inhibiting the
expression of TFAM and NRF1, two crucial nuclear regulators of mitochondrial biogenesis.
Moreover, we determined that nuclear FBP2 colocalizes with the c-Myc transcription factor at the
TFAM promoter region and represses c-Myc-dependent TFAM activation. Collectively, these data
add to our current understanding of FBP2’s role in sarcoma progression and provide implications
for STS metabolic reprogramming that should guide future clinical treatment.

Future directions
Restoring FBP2 expression in soft tissue sarcoma.
Previous studies have shown that FBP1 epigenetic repression is common in several cancers,
such as hepatocellular carcinoma (HCC), and colon and non-small cell lung, and breast cancer
(Bigl et al., 2008; Chen et al., 2011; Liu et al., 2018). Specifically, in breast cancer cells, histone
methyltransferase G9a and DNA methyltransferase DNMT1 are recruited to the FBP1 promoter by
Snail, a critical factor in epithelial-to-mesenchymal transitions (EMTs), resulting in increased
H3K9me2 and DNA methylation (Dong et al., 2013). Similarly, in lung cancer cells, zinc finger Ebox-binding homeobox 1 (ZEB1) increases DNA methylation by binding to FBP1’s promoter (Zhang
et al., 2016). In addition, pharmacological inhibition of histone demethylase LSD1 by
tranylcypromine remarkably upregulated FBP1 expression (Pan et al., 2013). Histone deacetylation
is also involved in downregulating FBP1, as low FBP1 levels are correlated with high levels of
histone deacetylase 1 (HDAC1) and HDAC2 proteins, and decreased histone H3K27 acetylation
at FBP1’s enhancer in HCC patient tissues (Yang et al., 2017). Importantly, HDAC inhibitors, such
as sodium butyrate, SAHA and LBH589, restored FBP1 expression in a dose-dependent manner
(Yang et al., 2017). Interestingly, ubiquitin-mediated degradation provides another layer of
regulation of FBP1 protein abundance in HCC, in that MAGE-A3 and MAGE-C2, which are known
to be overexpressed in HCC, form ubiquitin ligase complexes with the tripartite motif-containing
protein 28 (TRIM28) and facilitate TRIM28-dependent degradation of FBP1 (Jin et al., 2017).
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As discussed above, diverse inhibitors of deacetylases or methyltransferases have been
examined in cancers exhibiting FBP1 silencing. In Chapter 3, I showed that FBP2 expression is
uniformly downregulated in a broad spectrum of sarcoma subtypes (Figure 2-3). Analysis of TCGA
sarcoma database indicates that FBP2 loss is not due to copy number variation, but rather through
epigenetic silencing, such as DNA and histone hypermethylation (data not shown). However, in
sarcoma cells, epigenetic profiling and associated transcription factors at the FBP2 promoter
remain to be uncovered. Therefore, it will be interesting to investigate the underlying mechanisms
of FBP2 downregulation, and test several epigenetic inhibitors or activators to restore FBP2
expression in sarcoma cells in the future.

Investigating the role of FBP2 in sarcoma initiation.
In this thesis, the main question I asked is: how is FBP2 loss affects sarcoma progression?
However, FBP2 mRNA levels are significantly decreased in tumors at early stages relative to
normal tissues, strongly indicating that FBP2 depletion is an essential step during sarcomagenesis.
To determine whether FBP2 loss contributes to sarcoma initiation, we will delete FBP2 in a
genetically engineered sarcoma mouse model, and assess whether FBP2 loss accelerates tumor
formation. Our lab utilizes a “KP” murine model, where adenovirus-expressing Cre recombinase
(Adeno-Cre) injection into gastrocnemius muscle simultaneously drives expression of oncogeneic
KrasG12D and deletion of Trp53 (Eisinger-Mathason et al., 2013; Kirsch et al., 2007; Mito et al.,
2009). These genetic changes occur frequently in sarcoma, and murine tumors that develop
recapitulate human UPS morphologically, histologically, and genetically. We will use a
CRISPR/Cas9 system to delete FBP2 in this KP model.

CRISPR-Cas9 knockin mice were

previously generated by inserting a Cas9 transgene expression cassette into the Cre-dependent
Rosa26 locus for genome editing and cancer modeling (Platt et al., 2014). We crossed the
CRISPR-Cas9 knockin mice with KP mice to generate Cas9KP mice, and therefore AAV-Cre
injection should simultaneously activate Cas9 and oncogenic Kras, and deplete p53. The use of
Cas9 mice in conjunction with sgRNA delivery allowed us to introduce an FBP2 knockout in the
same animal to more closely recapitulate the nature of mutation accumulation in evolving tumors.
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By comparing tumor initiation time between Cas9KP mice injected with AAV-Cre-sgLacZ or AAVCre-sgFBP2, we will be able to answer whether FBP2 loss is an essential event during early
sarcomagenesis.

Exploring the potential correlation between muscle differentiation and FBP2 subcellular
localization.
For some time, FBP2 has been considered as a key enzyme of glycogen synthesis, which is
soluble and freely diffused in the cytoplasm. However, a previous study indicates that in dividing
myoblasts, FBP2 is localized to both cytosol and nuclei; whereas in differentiated myofibers, FBP2
is restricted to the cytosolic compartment (Gizak et al., 2006). In addition, my preliminary data also
showed FBP2 translocation from nucleus to cytosol in human and mouse myoblast. Interestingly,
the nuclear-cytosolic shuttling during muscle differentiation is consistent with my findings of FBP2’s
specific functions in different cellular compartments described in this thesis. A shift from a highly
glycolytic state to relying predominantly on OXPHOS has been observed during skeletal myoblast
differentiation (Remels et al., 2010). We conclude that FBP2 is restricted to the nucleus in muscle
progenitors, and transcriptionally suppresses mitochondrial biogenesis and OXPHOS. At the onset
of differentiation, FBP2 exits the nucleus and functions as a gluconeogenic/glycogen producing
enzyme to antagonize glycolysis in the cytosol. Of note, previous studies showed that cytosolic
FBP2 binds to mitochondria and protects mitochondria from calcium-induced mitochondrial
swelling and ensures ATP production in cardiomyocytes (Gizak and Rakus, 2012; 2014). The
differential acts of FBP2 on mitochondria depends on its subcellular localizations, reflecting a
complex and exquisite control of energy usage on each differentiation stage of these cells.

A conserved nuclear localization sequence “203KKKGK207” was identified in FBP1 and FBP2
(Gizak et al., 2005; 2009a). Interestingly, a potential target of Casein Kinase 2, Ser 10, is located
closely to FBP2’s NLS sequence, suggesting that nuclear transport of FBP2 might be regulated by
phosphorylation of this amino acid residue (Gizak et al., 2005). We speculate that nutrient
availability and growth factor signaling affect FBP2 translocation, and therefore activate its different
functions in the cytosol and nucleus. However, the underlying mechanisms of FBP2 translocation
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and whether subcellular shuttling of FBP2 contributes to muscle differentiation are unclear, and
remain part of our future studies.

80

Bibliography
Ahmad, A., Aboukameel, A., Kong, D., Wang, Z., Sethi, S., Chen, W., Sarkar, F.H., and Raz, A.
(2011). Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal
transition regulated by miR-200 in breast cancer cells. Cancer Res. 71, 3400–3409.
Ahuatzi, D., Herrero, P., la Cera, de, T., and Moreno, F. (2004). The glucose-regulated nuclear
localization of hexokinase 2 in Saccharomyces cerevisiae is Mig1-dependent. Journal of
Biological Chemistry 279, 14440–14446.
Åsberg, C., Hjalmarson, O., Alm, J., Martinsson, T., Waldenström, J., and Hellerud, C. (2010).
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriolstimulated monocytes with a note on long-term prognosis. J Inherit Metab Dis 33, 113–121.
Barretina, J., Taylor, B.S., Banerji, S., Ramos, A.H., Lagos-Quintana, M., Decarolis, P.L., Shah,
K., Socci, N.D., Weir, B.A., Ho, A., et al. (2010). Subtype-specific genomic alterations define new
targets for soft-tissue sarcoma therapy. Nat. Genet. 42, 715–721.
Bigl, M., Jandrig, B., Horn, L.-C., and Eschrich, K. (2008). Aberrant methylation of human L- and
M-fructose 1,6-bisphosphatase genes in cancer. Biochemical and Biophysical Research
Communications 377, 720–724.
Birsoy, K., Wang, T., Chen, W.W., Freinkman, E., Abu-Remaileh, M., and Sabatini, D.M. (2015).
An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable
Aspartate Synthesis. Cell 162, 540–551.
Boukouris, A.E., Zervopoulos, S.D., and Michelakis, E.D. (2016). Metabolic Enzymes
Moonlighting in the Nucleus: Metabolic Regulation of Gene Transcription. Trends in Biochemical
Sciences 41, 712–730.

81

Brizel, D.M., Scully, S.P., Harrelson, J.M., Layfield, L.J., Bean, J.M., Prosnitz, L.R., and Dewhirst,
M.W. (1996). Tumor oxygenation predicts for the likelihood of distant metastases in human soft
tissue sarcoma. Cancer Res. 56, 941–943.
Buscaglia, C.A., Penesetti, D., Tao, M., and Nussenzweig, V. (2006). Characterization of an
aldolase-binding site in the Wiskott-Aldrich syndrome protein. Journal of Biological Chemistry
281, 1324–1331.
Cai, L., Sutter, B.M., Li, B., and Tu, B.P. (2011). Acetyl-CoA induces cell growth and proliferation
by promoting the acetylation of histones at growth genes. Molecular Cell 42, 426–437.
Cancer Genome Atlas Research Network (2017). Comprehensive and Integrated Genomic
Characterization of Adult Soft Tissue Sarcomas. Cell 171, 950–965.e28.
Castonguay, Z., Auger, C., Thomas, S.C., Chahma, M., and Appanna, V.D. (2014). Nuclear
lactate dehydrogenase modulates histone modification in human hepatocytes. Biochemical and
Biophysical Research Communications 454, 172–177.
Chatterjee, A., Dasgupta, S., and Sidransky, D. (2011). Mitochondrial Subversion in Cancer.
Cancer Prev Res 4, 638–654.
Chen, M., Zhang, J., Li, N., Qian, Z., Zhu, M., Li, Q., Zheng, J., Wang, X., and Shi, G. (2011).
Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma
and colon cancer. PLoS ONE 6, e25564.
Chen, X.J., Wang, X., Kaufman, B.A., and Butow, R.A. (2005). Aconitase couples metabolic
regulation to mitochondrial DNA maintenance. Science 307, 714–717.
Cheng, C., Ru, P., Geng, F., Liu, J., Yoo, J.Y., Wu, X., Cheng, X., Euthine, V., Hu, P., Guo, J.Y.,
et al. (2015). Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and
Tumor Growth. Cancer Cell 28, 569–581.

82

Cheung, E.C., Ludwig, R.L., and Vousden, K.H. (2012). Mitochondrial localization of TIGAR
under hypoxia stimulates HK2 and lowers ROS and cell death. Proc. Natl. Acad. Sci. U.S.a. 109,
20491–20496.
Chiara, F., Castellaro, D., Marin, O., Petronilli, V., Brusilow, W.S., Juhaszova, M., Sollott, S.J.,
Forte, M., Bernardi, P., and Rasola, A. (2008). Hexokinase II detachment from mitochondria
triggers apoptosis through the permeability transition pore independent of voltage-dependent
anion channels. PLoS ONE 3, e1852.
Cieśla, M., Mierzejewska, J., Adamczyk, M., Farrants, A.-K.Ö., and Boguta, M. (2014). Fructose
bisphosphate aldolase is involved in the control of RNA polymerase III-directed transcription.
Biochimica Et Biophysica Acta 1843, 1103–1110.
Courtney, K.D., Bezwada, D., Mashimo, T., Pichumani, K., Vemireddy, V., Funk, A.M., Wimberly,
J., McNeil, S.S., Kapur, P., Lotan, Y., et al. (2018). Isotope Tracing of Human Clear Cell Renal
Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo. Cell Metabolism 28, 793–
800.e2.
Dang, C.V., O'Donnell, K.A., Zeller, K.I., Nguyen, T., Osthus, R.C., and Li, F. (2006). The c-Myc
target gene network. Semin. Cancer Biol. 16, 253–264.
Detwiller, K.Y., Fernando, N.T., Segal, N.H., Ryeom, S.W., D'Amore, P.A., and Yoon, S.S.
(2005). Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA
interference of vascular endothelial cell growth factor A. Cancer Res. 65, 5881–5889.
Dickinson, A., Yeung, K.Y., Donoghue, J., Baker, M.J., Kelly, R.D., McKenzie, M., Johns, T.G.,
and John, J.C.S. (2013). The regulation of mitochondrial DNA copy number in glioblastoma cells.
Cell Death Differ 20, 1644.
Dong, C., Yuan, T., Wu, Y., Wang, Y., Fan, T.W.M., Miriyala, S., Lin, Y., Yao, J., Shi, J., Kang, T.,
et al. (2013). Loss of FBP1 by Snail-mediated repression provides metabolic advantages in
basal-like breast cancer. Cancer Cell 23, 316–331.
83

Eisinger-Mathason, T.S.K., Mucaj, V., Biju, K.M., Nakazawa, M.S., Gohil, M., Cash, T.P., Yoon,
S.S., Skuli, N., Park, K.M., Gerecht, S., et al. (2015). Deregulation of the Hippo pathway in softtissue sarcoma promotes FOXM1 expression and tumorigenesis. Proc. Natl. Acad. Sci. U.S.a.
112, E3402–E3411.
Eisinger-Mathason, T.S.K., Zhang, M., Qiu, Q., Skuli, N., Nakazawa, M.S., Karakasheva, T.,
Mucaj, V., Shay, J.E.S., Stangenberg, L., Sadri, N., et al. (2013). Hypoxia-dependent modification
of collagen networks promotes sarcoma metastasis. Cancer Discov 3, 1190–1205.
Enzo, E., Santinon, G., Pocaterra, A., Aragona, M., Bresolin, S., Forcato, M., Grifoni, D., Pession,
A., Zanconato, F., Guzzo, G., et al. (2015). Aerobic glycolysis tunes YAP/TAZ transcriptional
activity. Embo J. 34, e201490379–e201491370.
Faubert, B., Li, K.Y., Cai, L., Hensley, C.T., Kim, J., Zacharias, L.G., Yang, C., Do, Q.N.,
Doucette, S., Burguete, D., et al. (2017). Lactate Metabolism in Human Lung Tumors. Cell 171,
358–371.e359.
Feo, S., Arcuri, D., Piddini, E., Passantino, R., and Giallongo, A. (2000). ENO1 gene product
binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc
promoter-binding protein 1 (MBP-1). FEBS Letters 473, 47–52.
Fletcher, C.D.M. (2014). The evolving classification of soft tissue tumours - an update based on
the new 2013 WHO classification. Histopathology 64, 2–11.
Frith, A.E., Hirbe, A.C., and Van Tine, B.A. (2013). Novel pathways and molecular targets for the
treatment of sarcoma. Curr Oncol Rep 15, 378–385.
Fruman, D.A., Chiu, H., Hopkins, B.D., Bagrodia, S., Cantley, L.C., and Abraham, R.T. (2017).
The PI3K Pathway in Human Disease. Cell 170, 605–635.

84

Fu, M., Li, L., Albrecht, T., Johnson, J.D., Kojic, L.D., and Nabi, I.R. (2011). Autocrine motility
factor/phosphoglucose isomerase regulates ER stress and cell death through control of ER
calcium release. Cell Death Differ 18, 1057–1070.
Funasaka, T., Hu, H., Hogan, V., and Raz, A. (2007a). Down-regulation of phosphoglucose
isomerase/autocrine motility factor expression sensitizes human fibrosarcoma cells to oxidative
stress leading to cellular senescence. Journal of Biological Chemistry 282, 36362–36369.
Funasaka, T., Hu, H., Yanagawa, T., Hogan, V., and Raz, A. (2007b). Down-regulation of
phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial
transition of human lung fibrosarcoma cells. Cancer Res. 67, 4236–4243.
Gao, X., Wang, H., Yang, J.J., Liu, X., and Liu, Z.-R. (2012). Pyruvate kinase M2 regulates gene
transcription by acting as a protein kinase. Molecular Cell 45, 598–609.
Gentile, T.L., Lu, C., Lodato, P.M., Tse, S., Olejniczak, S.H., Witze, E.S., Thompson, C.B., and
Wellen, K.E. (2013). DNMT1 Is Regulated by ATP-Citrate Lyase and Maintains Methylation
Patterns during Adipocyte Differentiation. Mol. Cell. Biol. 33, 3864–3878.
Ghosh, A.K., Steele, R., and Ray, R.B. (1999a). Functional domains of c-myc promoter binding
protein 1 involved in transcriptional repression and cell growth regulation. Mol. Cell. Biol. 19,
2880–2886.
Ghosh, A.K., Steele, R., and Ray, R.B. (1999b). MBP-1 physically associates with histone
deacetylase for transcriptional repression. Biochemical and Biophysical Research
Communications 260, 405–409.
Gizak, A., and Dzugaj, A. (2003). FBPase is in the nuclei of cardiomyocytes. FEBS Letters 539,
51–55.
Gizak, A., Rakus, D., and Dzugaj, A. (2005). Nuclear Localization of Fructose 1,6-bisphosphatase
in Smooth Muscle Cells. J Mol Hist 36, 243–248.

85

Gizak, A., Wrobel, E., Moraczewski, J., and Dzugaj, A. (2006). Changes in subcellular localization
of fructose 1,6-bisphosphatase during differentiation of isolated muscle satellite cells. FEBS
Letters 580, 4042–4046.
Gizak, A., and Rakus, D. (2012). Muscle FBPase binds to cardiomyocyte mitochondria under
glycogen synthase kinase-3 inhibition or elevation of cellular Ca2+ level. FEBS Letters 586, 13–
19.
Gizak, A., and Rakus, D. (2014). Changes in quaternary structure of muscle fructose-1,6bisphosphatase regulate affinity of the enzyme to mitochondria. Int. J. Biochem 48, 55–59.
Gizak, A., Maciaszczyk-Dziubinska, E., Maciaszczyk-Dziubinska, E., Jurowicz, M., Jurowicz, M.,
and Rakus, D. (2009a). Muscle FBPase is targeted to nucleus by its 203KKKGK 207sequence.
Proteins 77, 262–267.
Gizak, A., Zarzycki, M., and Rakus, D. (2009b). Nuclear targeting of FBPase in HL-1 cells is
controlled by beta-1 adrenergic receptor-activated Gs protein signaling cascade. Biochimica Et
Biophysica Acta 1793, 871–877.
Gobble, R.M., Qin, L.-X., Brill, E.R., Angeles, C.V., Ugras, S., O'Connor, R.B., Moraco, N.H.,
Decarolis, P.L., Antonescu, C., and Singer, S. (2011). Expression profiling of liposarcoma yields a
multigene predictor of patient outcome and identifies genes that contribute to
liposarcomagenesis. Cancer Res. 71, 2697–2705.
Gottlob, K., Majewski, N., Kennedy, S., Kandel, E., Robey, R.B., and Hay, N. (2001). Inhibition of
early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and
mitochondrial hexokinase. Genes & Development 15, 1406–1418.
Grosse, F., Nasheuer, H.P., Scholtissek, S., and Schomburg, U. (1986). Lactate dehydrogenase
and glyceraldehyde-phosphate dehydrogenase are single-stranded DNA-binding proteins that
affect the DNA-polymerase-alpha-primase complex. Eur. J. Biochem. 160, 459–467.

86

Hara, M.R., Agrawal, N., Kim, S.F., Cascio, M.B., Fujimuro, M., Ozeki, Y., Takahashi, M., Cheah,
J.H., Tankou, S.K., Hester, L.D., et al. (2005). S-nitrosylated GAPDH initiates apoptotic cell death
by nuclear translocation following Siah1 binding. Nature Cell Biology 7, 665–674.
Hay, N. (2016). Reprogramming glucose metabolism in cancer: can it be exploited for cancer
therapy? Nat Rev Cancer 16, 635–649.
Hirata, H., Sugimachi, K., Komatsu, H., Ueda, M., Masuda, T., Uchi, R., Sakimura, S., Nambara,
S., Saito, T., Shinden, Y., et al. (2016). Decreased Expression of Fructose-1,6-bisphosphatase
Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma.
Cancer Res. 76, 3265–3276.
Hosios, A.M., Fiske, B.P., Gui, D.Y., and Vander Heiden, M.G. (2015). Lack of Evidence for
PKM2 Protein Kinase Activity. Molecular Cell 59, 850–857.
Hosios, A.M., Hecht, V.C., Danai, L.V., Johnson, M.O., Rathmell, J.C., Steinhauser, M.L.,
Manalis, S.R., and Vander Heiden, M.G. (2016). Amino Acids Rather than Glucose Account for
the Majority of Cell Mass in Proliferating Mammalian Cells. Dev. Cell 36, 540–549.
Hsu, K.-W., Hsieh, R.-H., Lee, Y.-H.W., Chao, C.-H., Wu, K.-J., Tseng, M.-J., and Yeh, T.-S.
(2008). The activated Notch1 receptor cooperates with alpha-enolase and MBP-1 in modulating
c-myc activity. Mol. Cell. Biol. 28, 4829–4842.
Huangyang, P., and Simon, M.C. (2018). Hidden features: exploring the non-canonical functions
of metabolic enzymes. Dis Model Mech 11, dmm033365.
Humpton, T.J., and Vousden, K.H. (2016). Regulation of Cellular Metabolism and Hypoxia by
p53. Cold Spring Harb Perspect Med 6, a026146.
Ishitani, R., Kimura, M., Sunaga, K., Katsube, N., Tanaka, M., and Chuang, D.M. (1996). An
antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-

87

induced apoptosis of mature cerebrocortical neurons in culture. J. Pharmacol. Exp. Ther. 278,
447–454.
Ishitani, R., and Chuang, D.-M. (1996). Glyceraldehyde-3-phosphate dehydrogenase antisense
oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured
cerebellar. Proc. Natl. Acad. Sci. U.S.a. 93, 1–5.
Jiang, Y., Li, X., Yang, W., Hawke, D.H., Zheng, Y., Xia, Y., Aldape, K., Wei, C., Guo, F., Chen,
Y., et al. (2014a). PKM2 regulates chromosome segregation and mitosis progression of tumor
cells. Molecular Cell 53, 75–87.
Jiang, Y., Qian, X., Shen, J., Wang, Y., Li, X., Liu, R., Xia, Y., Chen, Q., Peng, G., Lin, S.-Y., et al.
(2015). Local generation of fumarate promotes DNA repair through inhibition of histone H3
demethylation. Nat. Cell Biol. 17, 1158–1168.
Jiang, Y., Wang, Y., Wang, T., Hawke, D.H., Zheng, Y., Li, X., Zhou, Q., Majumder, S., Bi, E., Liu,
D.X., et al. (2014b). PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells. Nat
Commun 5, 5566.
Jin, X., Pan, Y., Wang, L., Zhang, L., Ravichandran, R., Potts, P.R., Jiang, J., Wu, H., and Huang,
H. (2017). MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma
progression by targeting FBP1 for degradation. Oncogenesis 6, e312–e312.
Kaelin, W.G., and McKnight, S.L. (2013). Influence of metabolism on epigenetics and disease.
Cell 153, 56–69.
Kao, A.W., Noda, Y., Johnson, J.H., Pessin, J.E., and Saltiel, A.R. (1999). Aldolase mediates the
association of F-actin with the insulin-responsive glucose transporter GLUT4. Journal of
Biological Chemistry 274, 17742–17747.

88

Katoh, Y., Ikura, T., Hoshikawa, Y., Tashiro, S., Ito, T., Ohta, M., Kera, Y., Noda, T., and Igarashi,
K. (2011). Methionine adenosyltransferase II serves as a transcriptional corepressor of Maf
oncoprotein. Molecular Cell 41, 554–566.
Kelly, D.P., and Scarpulla, R.C. (2004). Transcriptional regulatory circuits controlling
mitochondrial biogenesis and function. Genes & Development 18, 357–368.
Kim, J.-W., and Dang, C.V. (2005). Multifaceted roles of glycolytic enzymes. Trends in
Biochemical Sciences 30, 142–150.
Kim, J.-W., Tchernyshyov, I., Semenza, G.L., and Dang, C.V. (2006). HIF-1-mediated expression
of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia.
Cell Metabolism 3, 177–185.
Kirsch, D.G., Dinulescu, D.M., Miller, J.B., Grimm, J., Santiago, P.M., Young, N.P., Nielsen, G.P.,
Quade, B.J., Chaber, C.J., Schultz, C.P., et al. (2007). A spatially and temporally restricted
mouse model of soft tissue sarcoma. Nat. Med. 13, 992–997.
Kumble, K.D., and Vishwanatha, J.K. (1991). Immunoelectron microscopic analysis of the
intracellular distribution of primer recognition proteins, annexin 2 and phosphoglycerate kinase, in
normal and transformed cells. J. Cell. Sci. 99, 751–758.
La Cera, De, T., Herrero, P., Moreno-Herrero, F., Chaves, R.S., and Moreno, F. (2002). Mediator
factor Med8p interacts with the hexokinase 2: implication in the glucose signalling pathway of
Saccharomyces cerevisiae. J. Mol. Biol. 319, 703–714.
Lee, J.V., Carrer, A., Shah, S., Snyder, N.W., Wei, S., Venneti, S., Worth, A.J., Yuan, Z.-F., Lim,
H.-W., Liu, S., et al. (2014). Akt-dependent metabolic reprogramming regulates tumor cell histone
acetylation. Cell Metabolism 20, 306–319.
Lee, J., Kim, H.K., Han, Y.-M., and Kim, J. (2008). Pyruvate kinase isozyme type M2 (PKM2)
interacts and cooperates with Oct-4 in regulating transcription. Int. J. Biochem 40, 1043–1054.

89

Lee, K.-M., Giltnane, J.M., Balko, J.M., Schwarz, L.J., Guerrero-Zotano, A.L., Hutchinson, K.E.,
Nixon, M.J., Estrada, M.V., Sánchez, V., Sanders, M.E., et al. (2017). MYC and MCL1
Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of
Mitochondrial Oxidative Phosphorylation. Cell Metabolism 26, 633–647.e637.
Lee, S.M., Kim, J.H., Cho, E.J., and Youn, H.D. (2009). A nucleocytoplasmic malate
dehydrogenase regulates p53 transcriptional activity in response to metabolic stress. Cell Death
Differ 16, 738–748.
Lee, W.N., Boros, L.G., Puigjaner, J., Bassilian, S., Lim, S., and Cascante, M. (1998). Mass
isotopomer study of the nonoxidative pathways of the pentose cycle with [1,2-13C2]glucose. Am.
J. Physiol. 274, E843–E851.
Lehnhardt, M., Daigeler, A., Homann, H.H., Schwaiberger, V., Goertz, O., Kuhnen, C., and
Steinau, H.U. (2009). MFH revisited: outcome after surgical treatment of undifferentiated
pleomorphic or not otherwise specified (NOS) sarcomas of the extremities -- an analysis of 140
patients. Langenbecks Arch Surg 394, 313–320.
Li, B., Li, B., Qiu, B., Qiu, B., Lee, D.S.M., Lee, D.S.M., Walton, Z.E., Walton, Z.E., Ochocki, J.D.,
Ochocki, J.D., et al. (2014). Fructose-1,6-bisphosphatase opposes renal carcinoma progression.
Nature 513, 251–255.
Li, F., Wang, Y., Zeller, K.I., Potter, J.J., Wonsey, D.R., O'Donnell, K.A., Kim, J.-W., Yustein, J.T.,
Lee, L.A., and Dang, C.V. (2005). Myc stimulates nuclearly encoded mitochondrial genes and
mitochondrial biogenesis. Mol. Cell. Biol. 25, 6225–6234.
Li, S., Swanson, S.K., Gogol, M., Florens, L., Washburn, M.P., Workman, J.L., and Suganuma, T.
(2015). Serine and SAM Responsive Complex SESAME Regulates Histone Modification
Crosstalk by Sensing Cellular Metabolism. Molecular Cell 60, 408–421.
Li, X., Qian, X., and Lu, Z. (2017a). Local histone acetylation by ACSS2 promotes gene
transcription for lysosomal biogenesis and autophagy. Autophagy 13, 1790–1791.
90

Li, X., Yu, W., Qian, X., Xia, Y., Zheng, Y., Lee, J.-H., Li, W., Lyu, J., Rao, G., Zhang, X., et al.
(2017b). Nucleus-Translocated ACSS2 Promotes Gene Transcription for Lysosomal Biogenesis
and Autophagy. Molecular Cell 66, 684–697.e689.
Lien, E.C., Lyssiotis, C.A., and Cantley, L.C. (2016). Metabolic Reprogramming by the PI3K-AktmTOR Pathway in Cancer. Recent Results Cancer Res. 207, 39–72.
Lincet, H., and Icard, P. (2015). How do glycolytic enzymes favour cancer cell proliferation by
nonmetabolic functions? Oncogene 34, 3751–3759.
Linch, M., Miah, A.B., Thway, K., Judson, I.R., and Benson, C. (2014). Systemic treatment of softtissue sarcoma-gold standard and novel therapies. Nat Rev Clin Oncol 11, 187–202.
Liu, G.-M., Li, Q., Zhang, P.-F., Shen, S.-L., Xie, W.-X., Chen, B., Wu, J., Hu, W.-J., Huang, X.-Y.,
and Peng, B.-G. (2018). Restoration of FBP1 suppressed Snail-induced epithelial to
mesenchymal transition in hepatocellular carcinoma. Cell Death Dis 9, 1132–12.
Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R.N., Pandey, A., and
Semenza, G.L. (2011). Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxiainducible factor 1. Cell 145, 732–744.
Majewski, N., Nogueira, V., Bhaskar, P., Coy, P.E., Skeen, J.E., Gottlob, K., Chandel, N.S.,
Thompson, C.B., Robey, R.B., and Hay, N. (2004). Hexokinase-mitochondria interaction
mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak.
Molecular Cell 16, 819–830.
McEwen, B.S., Allfrey, V.G., and Mirsky, A.E. (1963). Studies on Energy-Yielding Reactions in
Thymus Nuclei. 2. Pathways of Aerobic Carbohydrate Catabolism. 238, 2571–2578.
Mehren, von, M., Randall, R.L., Benjamin, R.S., Boles, S., Bui, M.M., Ganjoo, K.N., George, S.,
Gonzalez, R.J., Heslin, M.J., Kane, J.M., et al. (2018). Soft Tissue Sarcoma, Version 2.2018,
NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16, 536–563.

91

Mito, J.K., Riedel, R.F., Dodd, L., Lahat, G., Lazar, A.J., Dodd, R.D., Stangenberg, L., Eward,
W.C., Hornicek, F.J., Yoon, S.S., et al. (2009). Cross species genomic analysis identifies a
mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS
ONE 4, e8075.
Mizunuma, H., and Tashima, Y. (1990). Survey of fructose 1,6-bisphosphatase isoenzyme in rat
organs and ontogenic expression of the enzyme in rat fetus. Int. J. Biochem 22, 883–887.
Morrish, F., Giedt, C., and Hockenbery, D. (2003). c-MYC apoptotic function is mediated by NRF1 target genes. Genes & Development 17, 240–255.
Moullan, N., Mouchiroud, L., Wang, X., Ryu, D., Williams, E.G., Mottis, A., Jovaisaite, V.,
Frochaux, M.V., Quiros, P.M., Deplancke, B., et al. (2015). Tetracyclines Disturb Mitochondrial
Function across Eukaryotic Models: A Call for Caution in Biomedical Research. Cell Rep 10,
1681–1691.
Nakazawa, M.S., Eisinger-Mathason, T.S.K., Sadri, N., Ochocki, J.D., Gade, T.P.F., Amin, R.K.,
and Simon, M.C. (2016a). Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma
growth. Nat Commun 7, 10539.
Nakazawa, M.S., Keith, B., and Simon, M.C. (2016b). Oxygen availability and metabolic
adaptations. Nat Rev Cancer 16, 663–673.
Neary, C.L., and Pastorino, J.G. (2013). Akt inhibition promotes hexokinase 2 redistribution and
glucose uptake in cancer cells. J. Cell. Physiol. 228, 1943–1948.
Newsholme, E.A., and Crabtree, B. (1970). The role of fructose-1,6-diphosphatase in the
regulation of glycolysis in skeletal muscle. FEBS Letters 7, 195–198.
Nickerson, M.L., Jaeger, E., Shi, Y., Durocher, J.A., Mahurkar, S., Zaridze, D., Matveev, V.,
Janout, V., Kollarova, H., Bencko, V., et al. (2008). Improved identification of von Hippel-Lindau
gene alterations in clear cell renal tumors. Clin. Cancer Res. 14, 4726–4734.

92

Nissim, I., Horyn, O., Nissim, I., Daikhin, Y., Wehrli, S.L., Yudkoff, M., and Matschinsky, F.M.
(2012). Effects of a glucokinase activator on hepatic intermediary metabolism: study with 13Cisotopomer-based metabolomics. Biochem. J. 444, 537–551.
Pan, D., Mao, C., and Wang, Y.-X. (2013). Suppression of gluconeogenic gene expression by
LSD1-mediated histone demethylation. PLoS ONE 8, e66294.
Pastorino, J.G., Shulga, N., and Hoek, J.B. (2002). Mitochondrial binding of hexokinase II inhibits
Bax-induced cytochrome c release and apoptosis. Journal of Biological Chemistry 277, 7610–
7618.
Phillips, D., Aponte, A.M., French, S.A., Chess, D.J., and Balaban, R.S. (2009). Succinyl-CoA
synthetase is a phosphate target for the activation of mitochondrial metabolism. Biochemistry 48,
7140–7149.
Platt, R.J., Chen, S., Zhou, Y., Yim, M.J., Swiech, L., Kempton, H.R., Dahlman, J.E., Parnas, O.,
Eisenhaure, T.M., Jovanovic, M., et al. (2014). CRISPR-Cas9 knockin mice for genome editing
and cancer modeling. Cell 159, 440–455.
Popanda, O., Fox, G., and Thielmann, H.W. (1998). Modulation of DNA polymerases alpha, delta
and epsilon by lactate dehydrogenase and 3-phosphoglycerate kinase. Biochimica Et Biophysica
Acta 1397, 102–117.
Remels, A.H.V., Langen, R.C.J., Schrauwen, P., Schaart, G., Schols, A.M.W.J., and Gosker, H.R.
(2010). Regulation of mitochondrial biogenesis during myogenesis. Mol. Cell. Endocrinol. 315,
113–120.
Ritterson Lew, C., and Tolan, D.R. (2012). Targeting of several glycolytic enzymes using RNA
interference reveals aldolase affects cancer cell proliferation through a non-glycolytic mechanism.
287, 42554–42563.

93

Rossignol, R., Gilkerson, R., Aggeler, R., Yamagata, K., Remington, S.J., and Capaldi, R.A.
(2004). Energy substrate modulates mitochondrial structure and oxidative capacity in cancer
cells. Cancer Res. 64, 985–993.
Sadri, N., and Zhang, P.J. (2013). Hypoxia-inducible factors: mediators of cancer progression;
prognostic and therapeutic targets in soft tissue sarcomas. Cancers 5, 320–333.
Scarpulla, R.C. (2008). Transcriptional paradigms in mammalian mitochondrial biogenesis and
function. Physiol. Rev. 88, 611–638.
Scarpulla, R.C. (2012). Nucleus-encoded regulators of mitochondrial function: integration of
respiratory chain expression, nutrient sensing and metabolic stress. Biochimica Et Biophysica
Acta 1819, 1088–1097.
Schieber, M., and Chandel, N.S. (2014). ROS function in redox signaling and oxidative stress.
Curr. Biol. 24, R453–R462.
Sellers, K., Fox, M.P., Bousamra, M., Slone, S.P., Higashi, R.M., Miller, D.M., Wang, Y., Yan, J.,
Yuneva, M.O., Deshpande, R., et al. (2015). Pyruvate carboxylase is critical for non-small-cell
lung cancer proliferation. J. Clin. Invest. 125, 687–698.
Sen, N., Hara, M.R., Ahmad, A.S., Cascio, M.B., Kamiya, A., Ehmsen, J.T., Agrawal, N.,
Aggrawal, N., Hester, L., Doré, S., et al. (2009). GOSPEL: a neuroprotective protein that binds to
GAPDH upon S-nitrosylation. Neuron 63, 81–91.
Sen, N., Hara, M.R., Kornberg, M.D., Cascio, M.B., Bae, B.-I., Shahani, N., Thomas, B., Dawson,
T.M., Dawson, V.L., Snyder, S.H., et al. (2008). Nitric oxide-induced nuclear GAPDH activates
p300/CBP and mediates apoptosis. Nat. Cell Biol. 10, 866–873.
Shaw, J.H.F., Humberstone, D.M., and Wolfe, R.R. (1988). Energy and Protein Metabolism in
Sarcoma Patients. Annals of Surgery 207, 283–289.

94

Si, W., Huang, W., Zheng, Y., Yang, Y., Liu, X., Shan, L., Zhou, X., Wang, Y., Su, D., Gao, J., et
al. (2015). Dysfunction of the Reciprocal Feedback Loop between GATA3- and ZEB2-Nucleated
Repression Programs Contributes to Breast Cancer Metastasis. Cancer Cell 27, 822–836.
Siegel, R.L., Miller, K.D., and Jemal, A. (2019). Cancer statistics, 2019. CA Cancer J Clin 97,
3133.
Sivanand, S., Rhoades, S., Jiang, Q., Lee, J.V., Benci, J., Zhang, J., Yuan, S., Viney, I., Zhao, S.,
Carrer, A., et al. (2017). Nuclear Acetyl-CoA Production by ACLY Promotes Homologous
Recombination. Molecular Cell 67, 252–265.
Sun, Y.J., Chou, C.C., Chen, W.S., Wu, R.T., Meng, M., and Hsiao, C.D. (1999). The crystal
structure of a multifunctional protein: phosphoglucose isomerase/autocrine motility
factor/neuroleukin. Proc. Natl. Acad. Sci. U.S.a. 96, 5412–5417.
Sundararaj, K.P., Wood, R.E., Ponnusamy, S., Salas, A.M., Szulc, Z., Bielawska, A., Obeid, L.M.,
Hannun, Y.A., and Ogretmen, B. (2004). Rapid shortening of telomere length in response to
ceramide involves the inhibition of telomere binding activity of nuclear glyceraldehyde-3phosphate dehydrogenase. Journal of Biological Chemistry 279, 6152–6162.
Sutendra, G., Kinnaird, A., Dromparis, P., Paulin, R., Stenson, T.H., Haromy, A., Hashimoto, K.,
Zhang, N., Flaim, E., and Michelakis, E.D. (2014). A Nuclear Pyruvate Dehydrogenase Complex
Is Important for the Generation of Acetyl-CoA and Histone Acetylation. Cell 158, 84–97.
Taylor, B.S., Barretina, J., Maki, R.G., Antonescu, C.R., Singer, S., and Ladanyi, M. (2011).
Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer 11, 541–557.
Tejwani, G.A. (1983). Regulation of fructose-bisphosphatase activity. Adv. Enzymol. Relat. Areas
Mol. Biol. 54, 121–194.
Vander Heiden, M.G., and DeBerardinis, R.J. (2017). Understanding the Intersections between
Metabolism and Cancer Biology. Cell 168, 657–669.

95

Wang, H.-J., Hsieh, Y.-J., Cheng, W.-C., Lin, C.-P., Lin, Y.-S., Yang, S.-F., Chen, C.-C., Izumiya,
Y., Yu, J.-S., Kung, H.-J., et al. (2014). JMJD5 regulates PKM2 nuclear translocation and
reprograms HIF-1α-mediated glucose metabolism. Proc. Natl. Acad. Sci. U.S.a. 111, 279–284.
Wang, W., Wang, L., Endoh, A., Hummelke, G., Hawks, C.L., and Hornsby, P.J. (2005).
Identification of alpha-enolase as a nuclear DNA-binding protein in the zona fasciculata but not
the zona reticularis of the human adrenal cortex. J. Endocrinol. 184, 85–94.
Wang, Z., and Dong, C. (2019). Gluconeogenesis in Cancer: Function and Regulation of PEPCK,
FBPase, and G6Pase. Trends Cancer 5, 30–45.
Warburg, O. (1956). On respiratory impairment in cancer cells. Science 124, 269–270.
Watanabe, H., Takehana, K., Date, M., Shinozaki, T., and Raz, A. (1996). Tumor cell autocrine
motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res. 56, 2960–
2963.
Weinberg, S.E., and Chandel, N.S. (2015). Targeting mitochondria metabolism for cancer
therapy. 11, 9–15.
Wellen, K.E., Hatzivassiliou, G., Sachdeva, U.M., Bui, T.V., Cross, J.R., and Thompson, C.B.
(2009). ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324, 1076–
1080.
Yalcin, A., Clem, B.F., Imbert-Fernandez, Y., Ozcan, S.C., Peker, S., O'Neal, J., Klarer, A.C.,
Clem, A.L., Telang, S., and Chesney, J. (2014). 6-Phosphofructo-2-kinase (PFKFB3) promotes
cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell
Death Dis 5, e1337.
Yalcin, A., Clem, B.F., Simmons, A., Lane, A., Nelson, K., Clem, A.L., Brock, E., Siow, D.,
Wattenberg, B., Telang, S., et al. (2009). Nuclear targeting of 6-phosphofructo-2-kinase

96

(PFKFB3) increases proliferation via cyclin-dependent kinases. Journal of Biological Chemistry
284, 24223–24232.
Yang, J., Jin, X., Yan, Y., Shao, Y., Pan, Y., Roberts, L.R., Zhang, J., Huang, H., and Jiang, J.
(2017). Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular
carcinoma growth by restoring FBP1 expression. Sci. Rep. 7, 43864.
Yang, W., Xia, Y., Cao, Y., Zheng, Y., Bu, W., Zhang, L., You, M.J., Koh, M.Y., Cote, G., Aldape,
K., et al. (2012a). EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation
upregulates PKM2 expression and promotes tumorigenesis. Molecular Cell 48, 771–784.
Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., Gao, X., Aldape, K., and Lu, Z. (2011).
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 480, 118–122.
Yang, W., Zheng, Y., Xia, Y., Ji, H., Chen, X., Guo, F., Lyssiotis, C.A., Aldape, K., Cantley, L.C.,
and Lu, Z. (2012b). ERK1/2-dependent phosphorylation and nuclear translocation of PKM2
promotes the Warburg effect. Nat. Cell Biol. 14, 1295–1304.
Yogev, O., Yogev, O., Singer, E., Shaulian, E., Goldberg, M., Fox, T.D., and Pines, O. (2010).
Fumarase: a mitochondrial metabolic enzyme and a cytosolic/nuclear component of the DNA
damage response. PLoS Biol. 8, e1000328.
Yuan, T.L., and Cantley, L.C. (2008). PI3K pathway alterations in cancer: variations on a theme.
Oncogene 27, 5497–5510.
Zhang, J., Wang, J., Xing, H., Li, Q., Zhao, Q., and Li, J. (2016). Down-regulation of FBP1 by
ZEB1-mediated repression confers to growth and invasion in lung cancer cells. Mol. Cell.
Biochem. 411, 331–340.
Zhao, S., Torres, A., Henry, R.A., Trefely, S., Wallace, M., Lee, J.V., Carrer, A., Sengupta, A.,
Campbell, S.L., Kuo, Y.-M., et al. (2016). ATP-Citrate Lyase Controls a Glucose-to-Acetate
Metabolic Switch. Cell Rep 17, 1037–1052.

97

Zheng, H., Gupta, V., Patterson-Fortin, J., Bhattacharya, S., Katlinski, K., Wu, J., Varghese, B.,
Carbone, C.J., Aressy, B., Fuchs, S.Y., et al. (2013). A BRISC-SHMT complex deubiquitinates
IFNAR1 and regulates interferon responses. Cell Rep 5, 180–193.
Zheng, L., Roeder, R.G., and Luo, Y. (2003). S phase activation of the histone H2B promoter by
OCA-S, a coactivator complex that contains GAPDH as a key component. Cell 114, 255–266.
Zhou, Y., Yi, X., Stoffer, J.B., Bonafe, N., Gilmore-Hebert, M., McAlpine, J., and Chambers, S.K.
(2008). The multifunctional protein glyceraldehyde-3-phosphate dehydrogenase is both regulated
and controls colony-stimulating factor-1 messenger RNA stability in ovarian cancer. Mol. Cancer
Res. 6, 1375–1384.
Zhu, Y., Shi, M., Chen, H., Gu, J., Zhang, J., Shen, B., Deng, X., Xie, J., Zhan, X., and Peng, C.
(2015). NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity
of pancreatic cancer cells. Oncotarget 6, 21443–21451.

98

